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Abstract  
Electrostatic interactions associated with aggrecan, one of the major components of the 
cartilage extracellular matrix, are responsible for ~50% of the equilibrium compressive 
elastic modulus of the tissue. The bottle-brush-shaped aggrecan consists of a core protein 
to which ~100 sulfated glycosaminoglycan (sGAG) chains are attached. Loss of sGAG is 
one early events in the pathogenesis of osteoarthritis and the resulting degradation of 
cartilage is irreversible due to its limited capacity for self-repair. Tissue engineering is 
one of the techniques which holds great potential for cartilage repair. In order to achieve 
successful repair, a clear understanding of native and engineered cartilage aggrecan is 
essential. 
With atomic force microscopy and high resolution force microscopy, the structure of 
aggrecan single molecules and the nanomechanical properties of an end-grafted aggrecan 
monolayer were quantified. Adult human aggrecan showed significantly shorter GAG 
chains and core proteins as well as lower molecular stiffness compared to that of newborn 
aggrecan. After enzymatic digestion of chondroitin sulfate (CS) GAGs, keratan sulfate 
GAG chains were visualized near the N-terminal domain of a less extended core protein. 
Direct visualization of aggrecan aggregates confirmed the structure of the constituent 
hyaluronic acid, aggrecan G1 domain, and link protein. Increased flexibility of the core 
protein was found near the G1 domain, which may facilitate the aggregate self-assembly 
process. Aggregated and non-aggregated aggrecan both showed remarked flexibility (i.e., 
decreased extension ratio) when the aggrecan areal density increased. These findings on 
intra- and inter-molecular structure provide insights into the structure-property 
relationships of aggrecan in vivo. 
Aggrecan produced by animal-matched bone marrow stromal cells (BMSCs) and 
chondrocytes seeded in peptide hydrogel were evaluated for their age-associated structure 
and nanomechanical properties. Independent of age, BMSCs produced longer core 
proteins and GAG chains than the chondrocytes, suggesting that the BMSC-produced 
aggrecan was characteristic of that from young cartilage. Comparison of the adult 
BMSC-produced aggrecan with adult cartilage-extracted aggrecan revealed that adult 
 4
BMSC-aggrecan has a phenotype characteristic of young growth cartilage: primarily full-
length aggrecan core, longer GAG chains and a higher content of chondroitin-4-sulfate in 
the CS-GAG chains, the latter identified via fluorescence assisted carbohydrate 
electrophoresis. The nanomechanical stiffness of BMSC-aggrecan was demonstrably 
greater than that of cartilage-aggrecan at the same total sGAG (fixed charge) density. 
These results support the use of adult BMSCs for cell-based cartilage repair. 
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Chapter 1  
Introduction 
1.1 Background 
Articular cartilage is aneural, avascular and alymphatic structure [1]. It provides a low-
friction gliding surface covering all the diarthrodial joints, with increased compressive 
strength, and is known to be wear-resistant under normal circumstances. Throughout life, 
the tissue undergoes continual internal remodeling as the cells replace matrix 
macromolecules lost through degradation. Unfortunately, the intrinsic ability of cartilage 
to repair defects caused by mechanical injuries is poor and the mitotic and synthetic 
activities of chondrocyte decline with age. Damage to cartilage is irreversible and will 
progressively lead to premature osteoarthritis (OA). Cartilage tissue engineering is a field 
that holds great potential for improved treatment of congenital diseases, traumatic injuries, 
and degenerative processes due to aging and diseases such as OA [2]. However, the 
production of an integrated, functional tissue replacement with structural, chemical and 
mechanical properties similar to native tissue still remains a great challenge. With high 
resolution force microscopy, it is now possible to directly measure the ultrastructural and 
nanomechanical properties of cartilage components, which are important for studying age 
and OA progression and also potential criteria for evaluating the similarity of tissue 
engineered cartilage tissue to native cartilage tissue for the purpose of cartilage repair. 
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1.2 Objectives 
Aggrecan, one of the major molecular components of the cartilage ECM, is composed of 
a core protein to which many highly charged glycosaminoglycan (GAG) chains are 
attached. The ability of cartilage to resist compressive loads is often ascribed to the 
osmotic swelling pressure associated with the high density of negative charge groups 
present on aggrecan GAGs [3]. Thus, specific changes in the structure of aggrecan and 
the constituent GAGs can have profound effects on its molecular biophysical function 
within the tissue and the resulting biomechanical performance of cartilage. The goal of 
this research is to investigate the structure-function relationship of aggrecan and to 
develop criteria for evaluating the quality of aggrecan from native and tissue engineered 
cartilage tissue.  
The first goal of this thesis was to extend the Ph.D. thesis work by Laurel Ng on 
direct visualization of aggrecan single molecules via atomic force microscopy [4]. The 
high resolution imaging technique was utilized to reveal the intra-molecular structure of 
aggrecan and inter-molecular interactions with other cartilage molecules. The second 
goal was to measure the nanomechanical properties of aggrecan studied in the first goal 
utilizing the high resolution force microscopic techniques developed by Delphine Dean 
[5] and Lin Han [6]. By relating the nanomechanical properties to the molecular 
architecture, these studies contribute to a better understanding of the aggrecan structure-
biophysical properties in cartilage. The third goal was to utilize the above 
nanotechnologies in combination with conventional biochemical assessments to 
characterize aggrecan produced by tissue engineering methodologies. This study provides 
insight into the properties of engineering neo-cartilage tissue and create criteria for 
evaluating the cell source and culture conditions in order to engineer desired ECM 
assemblies. 
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1.3 Overview 
This thesis is structured as follows. Chapter 2 provides a brief overview of cartilage ECM 
and aggrecan, as well as the nanotechnologies utilized to probe their properties. A short 
background on cartilage tissue engineering is also included in Chapter 2. In Chapter 3, 
human aggrecan from donors of different ages is compared for their structural differences. 
Additional studies on the age-related change in nanomechanical properties of aggrecan 
are included in Appendix A. Chapter 4 contains the inter- and intra-molecular 
conformation of aggrecan monomers and aggregates. In Chapter 5, tissue engineered 
aggrecan produced by different cell sources and animal ages are characterized in order to 
determine the cell capacity of aggrecan synthesis. The comparison of tissue engineered 
aggrecan and native cartilage aggrecan is described in Chapter 6. Additional data of 
fluorescence assisted carbohydrate electrophoresis (FACE) analysis of equine cell-
peptide aggrecan are included in Appendix B. Chapter 7 summarizes these studies and 
future work. Appendix C and D contain extended studies of intervertebral discs aggrecan 
from human and porcine and characterizations of aggrecan from commercial sources. 
Appendices E-H describe the experiment protocols used in this thesis. 
 28
 29
Chapter 2  
Background 
Articular cartilage provides a low-friction gliding surface and shock absorbing 
cushioning between the bones. However, once damaged, articular cartilage lacks the 
ability to properly repair and regenerate itself. Recent advances in biology and material 
science have brought tissue engineering to the forefront of new cartilage repair 
techniques. A clear understanding of the native and engineered cartilage tissue is 
essential in order to ensure they have compatible biological and mechanical functions. 
With the advent of high resolution nanotechnological methods, nanometer-scale 
resolution of molecular structure and mechanical functionality can be achieved and 
utilized to provide additional single molecular information complementary to 
biochemical methods that involve a large ensemble of macromolecules.  
2.1 Cartilage and Aggrecan 
Cartilage has a highly organized extracellular matrix (ECM) which contains a fluid phase 
of water (68-85% of total weight) and a solid organic phase of ECM proteins. The 
production, organization and maintenance of the cartilage ECM are modulated by 
chondrocytes, the only cell type resident in articular cartilage. There are three classes of 
proteins in articular cartilage ECM: collagens (60-86% of dry weight), proteoglycans (15-
40% of dry weight), and other noncollagenous proteins (Figure 2-1a). 
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Aggrecan is the most abundant proteoglycan in cartilage. It is comprised of a core 
protein and two types of glycosaminoglycan (GAG) side chains, chondroitin sulfate (CS) 
and keratan sulfate (KS) (Figure 2-1b). The ability of articular cartilage to resist 
compression is primarily attributed to the CS GAG chains. A macroscale interpretation, 
independent of molecular structure, is that the high density of the fixed negative charges 
of the sulfate and carboxylate groups on CS GAG chains draws water into cartilage, 
resulting in high osmotic pressure, which is restrained by the collagen fiber network, thus 
giving rise to the compressive behavior of cartilage. At the molecular scale, it is the 
electrostatic double layer repulsive interaction forces between the rod-like GAG chains 
that gives rise to compressive stiffness. 
 
 
Figure 2-1: (a) Schematic illustration of molecular constituents in cartilage and their 
arrangement into large multi-molecular assemblies [7]. (b) Illustration of aggrecan 
structure and the specific cleavage sites by proteolytic enzymes [7]. (c) Toluidine blue-
stained sections of canine articular cartilage showing distribution of chondrocytes and 
GAGs in normal cartilage, and cartilage with early or late stage OA [8].  
The turnover of aggrecan is governed by its synthesis by chondrocytes and its 
degradation by proteolytic enzymes. The catabolism of aggrecan in vivo is believed to be 
mainly mediated by aggrecanases (Figure 2-1b), though matrix metalloproteinases 
(MMPs) may still be responsible for the appearance of specific fragments of aggrecan 
found in synovial fluids from OA and joint-injured patients [8]. MMPs and aggrecanases 
 a b CS 
KS
Normal Early OA Late OA c
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cleave aggrecan core proteins at specific sites and generate free C-terminal fragments 
which can diffuse rapidly out of the tissue [9]. Increased catabolism of the aggrecan is a 
principal pathological process (Figure 2-1c). The consequent net loss of sulfated GAGs 
compromises both the functional and structural integrity of the cartilage and ultimately 
renders the tissue incapable of resisting the compressive loads applied during joint 
articulation.  
Aggrecan also interacts with the other molecules in cartilage and is involved in 
matrix organization. Through its core protein N-terminal G1 domain, aggrecan is non-
covalently bound to hyaluronic acid (HA) to form higher order networks, stabilized by a 
second protein, the link protein binding non-covalently to both HA and the G1 domain of 
aggrecan (Figure 2-2) [10]. It has been shown more recently that the aggrecan C-terminal 
G3 domain can interact with certain matrix proteins containing EFG repeats [11]. The KS 
rich region has been shown to bind with high affinity for collagen [12], which may play a 
role in organizing ECM components. There are still many unanswered questions related 
to the fine structure of aggrecan and the specific functions of its subunits, e.g., the precise 
location of KS along various regions of the core protein, the extent of CS and KS 
substitution along the core between normal individuals and variations with age and OA, 
altered glycosylation patterns within the G1-G2 interglobular domain during aging and 
degeneration, and the function of the G2 and G3 globular domains [13]. 
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Figure 2-2: (a) Electron micrograph of an aggrecan aggregate and many free aggrecan 
monomers (b) Illustration of aggrecan aggregate and the intermolecular association. 
Images are adapted from [14]. 
2.2 Cartilage Tissue Engineering 
Cartilage tissue engineering is an emerging field which holds great potential to improve 
cartilage repair and regeneration. There are two basic approaches to cartilage tissue 
engineering: ex vivo tissue engineering, in which the tissue is generated entirely in vitro 
with full functionality before transplantation; in vivo tissue engineering, in which the 
construct is implanted with or without prior partial in vitro cultivation and allowed to 
mature in vivo for tissue repair and regeneration. Both approaches require appropriate 
scaffolds, responsive cells, and a chondroinductive and chondroconductive environment.  
The scaffold provides the form and shape, guides the orderly differentiation and 
development of the replacement tissue, and should be biocompatible and noncytotoxic 
[15]. Chondrocytes and stem cells are two potential cell candidates for cartilage tissue 
engineering. Although chondrocytes are the cells of choice for the dominant clinical cell 
based therapy for the repair of cartilage lesions over the past decade, the drawbacks in 
using chondrocytes include limited availability of source material, coupled with potential 
donor site morbidity, and the poor replicative capacity of chondrocytes that show rapid 
a b 
1 μm 
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dedifferentiation in monolayer expansion. Stem cells, defined by their ability to undergo 
self-renewal, replication and differentiation upon stimulation, are emerging as a more 
attractive alternative for cartilage tissue engineering. Moreover, the chondrogenic 
potential of stem cells seem to be independent of age or OA [16], which is an advantage 
of using stem cells over chondrocytes for autologous cell-based cartilage repair for older 
OA patients, where the source and capacity of chondrocytes are limited. To induce and 
maintain the chondrogenic phenotype of the cells, an environment consisting of 
appropriate biological and physical influence is crucial. Through the use of combinations 
of growth factors and various modes of mechanical stimulation, cartilage tissue 
engineering has generated tissue constructs with mechanical strength and proteoglycan 
and collagen contents approaching, although not quite as high as, those of native articular 
cartilage [17]. 
2.3 Atomic Force Microscopic Studies of Aggrecan 
Structural and Nanomechanical Properties 
2.3.1.  Single Molecule Imaging 
Ng et al. previously developed the sample preparation, imaging, and data analysis 
techniques to quantify the structure and conformation of individual aggrecan and its 
constituent GAGs [4]. Purified aggrecan was immobilized on aminosilane-functionalized 
mica substrates via electrostatic interaction and imaged with tapping mode AFM in 
ambient conditions. Direct visualization with distinct resolution of the aggrecan core 
protein domains and individual GAG chains was achieved (Figure 2-3). The structure of 
two aggrecan populations – bovine fetal epiphyseal and mature nasal cartilage aggrecan– 
were quantified and compared for the differences in core protein/GAG trace length, end-
to-end distance, and persistence length. The result showed that the fetal epiphyseal 
aggrecan has longer core protein trace length, longer GAG chain trace length, smaller 
GAG-GAG spacing, as well as larger persistence length, which is correlated with the 
higher equilibrium modulus of load-bearing and immature cartilage. The study 
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demonstrated that single molecule studies enable the quantification of molecular 
dimensional heterogeneity within a population with extremely high spatial sensitivity, 
while still permitting the determination of ensemble properties through the pooling of 
individual measurements. In conjunction with biochemical methodologies, the detailed 
structural variations of aggrecan as a function of age, disease and species can be studied 
to better understand the function of aggrecan in cartilage.  
 
Figure 2-3: Tapping mode AFM height images of individual (a) bovine fetal epiphyseal 
and (b) mature nasal aggrecan monomers. Images are adapted from [4].  
2.3.2.  Nanomechanics 
Dean et al. developed methodologies to quantify the nanoscale deformability and 
compressibility of cartilage aggrecan [5]. Micro-contact printing was employed to 
produce micrometer-sized patterned surfaces of densely packed, chemically end-grafted 
bovine cartilage aggrecan surrounded by a neutral hydroxyl-terminated self-assembled 
monolayer (Figure 2-4a). Aggrecan height (and, hence, conformation and compressibility) 
was measured by contact mode AFM as a function of normal load and found to be highly 
dependent on ionic strength (Figure 2-4b). High resolution force spectroscopy was then 
used to measure the nanoscale compressive forces between the AFM probe tip and the 
aggrecan functionalized substrate as a function of tip-substrate separation distance in 
0.001M-1M NaCl (Figure 2-4c). By combining the height versus normal load data with 
the force versus distance data, an effective stress versus strain curve was calculated 
(Figure 2-4d). Using lateral force microscopy, the shear behavior of aggrecan layers was 
 
 
 
1.1nm 
a b 
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also studied by Han et al. [18]. Together with AFM single molecule imaging, the 
nanomechanical testing can provide insights into the structure-function relationship of 
cartilage ECM constituents.  
 
Figure 2-4: (a) 3D AFM height image of the microcontact printed surface where the 
specific hexagonal region is functionalized by chemically end-grafting aggrecan to the 
substrate (gold) with the outer region functionalized by a hydroxy-terminated self-
assembling monolayer (OH-SAM). (b) Schematic of height vs. force experiment (c) 
Schematic of normal force vs. tip-substrate distance experiment (d) Corresponding stress 
versus strain for fetal epiphyseal and mature nasal aggrecan samples in 0.1M [NaCl]. 
Schematics adapted from [5]. 
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Chapter 3  
Structural Changes of Individual 
Human Cartilage Aggrecan 
Molecules Associated with Age and 
Deglycosylation 
3.1 Introduction 
Aggrecan, the most abundant proteoglycan in the extracellular matrix of cartilage, is a 
major molecular component that enables the tissue to perform its function as a load 
bearing material in articular joints. It is composed of a ~300 kDa core protein substituted 
with ~100 chondroitin sulfate (CS) and ~50 keratan sulfate (KS) glycosaminoglycan 
(GAG) chains, as well as N-linked and O-linked oligosaccharides [13]. The negatively 
charged GAG chains keep cartilage hydrated and create extremely high electrostatic 
repulsive forces that resist compression. In cartilage, aggrecan associates noncovalently 
with hyaluronic acid, stabilized by link protein, to form high molecular weight aggregates 
(>200 MDa) that are enmeshed within a reinforcing collagen fibril network. The unique 
matrix organization gives cartilage exceptional biomechanical properties including 
toughness, strength, and resiliency.  In addition to the direct mechanical function of 
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aggrecan in cartilage, the presence of aggrecan is also known to protect cartilage collagen 
from proteolytic cleavage [19], and to regulate matrix transport of nutrients [13]. 
Human aggrecan is known to exhibit significant structural heterogeneity with age, 
including differences in core protein and GAG chain length, KS and CS substitution, and 
CS sulfate ester substitution that is important in determining charge distribution and 
linear charge density [13,20-22].  Progressive C-terminal truncation of the core protein by 
proteolytic enzymes takes place with increasing maturation [23], and variations in 
aggrecan structure, in turn, can further modulate its susceptibility to aggrecanases [24]. 
Such age-related changes in aggrecan biochemical structure are believed to be directly 
linked to known age-related differences in the deformational behavior of normal human 
knee cartilage measured in vivo using MRI [25]. Degradation of aggrecan is also a 
hallmark of the initial stages of the clinical syndrome of osteoarthritis which results in the 
degeneration of cartilage function [8].   
While biochemical assays have characterized the age-related change of aggrecan 
structural compositions from the average result of a large macromolecule ensemble, they 
can not define the structure of individual aggrecan monomers or the degree of variability 
within the sample. High resolution imaging techniques, e.g., electron microscopy [1,26-
31] and atomic force microscopy (AFM) [32-34], thus are important for examining 
aggrecan structure at the molecular level. Previously, we have visualized individual 
aggrecan of different animal age and tissue types using AFM [4]. By comparing the 
structural parameters of the fetal bovine epiphyseal aggrecan and mature bovine nasal 
cartilage aggrecan, we reveal that the greater molecular stiffness of fetal bovine 
epiphyseal aggrecan molecules is highly attributed to the longer GAG chain length and 
smaller GAG-GAG spacing. 
In this present work, we utilized the techniques to examine human articular cartilage 
aggrecan. We quantified the structural dimensions of individual aggrecan molecules from 
donors of different ages. Furthermore, we visually separated the newly synthesized full-
length aggrecan from the entire observed aggrecan population which contains both the 
full-length molecules and the proteolytic degraded fragments, in order to decouple the 
effects of biosynthesis and proteolysis on aggrecan structure. Finally, we selectively 
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digested CS or KS GAG chains on aggrecan core proteins to examine the effect of GAG 
chains on core protein conformation and the spatial distribution of KS GAG chains. 
3.2 Materials and Methods 
3.2.1.  Aggrecan Isolation 
Microscopically normal human articular cartilage was obtained at autopsy from one 
newborn, one 29-year-old and one 38-year-old adult with whom there was no 
microscopic evidence of arthritic disease and no joint damage. Aggrecan was purified by 
dissociative CsCl density gradient centrifugation from 4 M guanidine HCl extracts of the 
cartilage as described previously [35]. The initial D1 fractions (>1.54 g/mL) of the 
newborn and 38-year-old human samples were subjected to a second dissociative CsCl 
density gradient centrifugation, whereas the 29-year-old human initial D1 fractions were 
treated with Keratanase II or Chondroitinase ABC prior to the second dissociative density 
gradient centrifugation (see below).  All the D1D1 fractions were dialyzed exhaustively 
against water, lyophilized, dissolved in water, and stored at -20 °C in 1 mg/ml aliquots.  
3.2.2.  Keratanase and Chondroitinase Treatment of Aggrecan 
The initial D1 fractions of the 29-year-old human aggrecan samples were treated with 
Keratanase II or Chondroitinase ABC in order to remove the KS or CS GAGs. The initial 
D1 fractions were incubated with 1 ml of a solution containing 100 mM Tris-HCl, pH 8.0, 
240 mM sodium acetate, 25 mM EDTA, and 0.02 units of protease-free chondroitinase 
ABC (Seikaguku Corp.) or 0.01 unit/100ml keratanase II (Seikagaku Kogyo, Tokyo, 
Japan) for 4 h at 37 °C. The digested samples were subsequently subjected to the second 
dissociative CsCl density gradient centrifugation, dialyzed, and stored as described in the 
previous section. 
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3.2.3.  AFM Sample Preparation and Imaging 
Procedures for aggrecan AFM sample preparation and imaging were described in [4]. 
Briefly, 50 µl aggrecan aliquots (~100 µg/ml GAG) were deposited on 3-
aminopropyltriethoxysilane (APTES; Sigma Aldrich, St. Louis, MO) treated muscovite 
mica surfaces (SPI Supplies, West Chester, PA, #1804 V-5) for 20-30 min at room 
temperature, rinsed gently with MilliQ water (Millipore, Billerica, MA) and air dried. 
The Nanoscope IIIa Multimode AFM (Digital Instruments, Santa Barbara, CA) was used 
to image all samples. Tapping mode was carried out in ambient conditions using probe 
tips with rectangular Si cantilevers (AC240TS-2, Olympus, k = 2 N/m, tip radius < 10 
nm). All imaging parameters were optimized to acquire high quality images.    
3.2.4.  Calculation of Trace and Effective Persistence Lengths from 
AFM Images 
The AFM height images were digitized into pixels and the aggrecan structure features 
were traced automatically with a custom Matlab program or manually with SigmaScan 
Pro image analysis software (SPSS Science, Chicago, IL). The core protein trace length 
LCP and GAG chain length LGAG were calculated according to the spatial coordinates of 
the traces. The 2D effective persistence length LP of aggrecan core proteins was 
calculated by applying the Krathky-Porod Worm-Like Chain (WLC) model [36] as 
described previously [4,37] . 
3.3 Results 
3.3.1.  Aggrecan Structural Dimension and Heterogeneity  
The single aggrecan monomer structure was directly visualized and the constituent GAG 
chains were clearly resolved in the AFM height images (Figure 3-1). The globular 
domains at the N- or C-terminals of aggrecan core proteins are distinct in the obtained 
images (Figure 3-1d-f, indicated by arrows). Aggrecan monomers consisting of globular 
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domains at both ends were defined as full-length aggrecan. Aggrecan fragments of 
various lengths were also observed.  
In all the obtained images, newborn aggrecan Figure 3-1a) were in general relatively 
uniform in size, whereas adult aggrecan (Figure 3-1b,c) exhibited greater heterogeneity in 
terms of core protein length and GAG chain length. There were more short fragments 
(~100 nm) bearing globular domains observed in the 29 and 38-year-old adult aggrecan 
images. The short fragments are presumably the accumulated “free G1” fragments after 
the proteolytic process.  
For all observed aggrecan, the lengths of core proteins LCP and constituent GAG 
chains LGAG of each individual aggrecan were traced as shown in Figure 3-1c. The LCP 
and LGAG distributions of all observed aggrecan are shown in Figure 3-2 and Figure 3-3 
(left column), respectively. The average LCP of newborn, 29 and 38-year-old aggrecan 
populations were found to be 473 ± 8 nm, 216 ± 10 nm and 348 ± 9 nm (Mean ± SEM), 
respectively; the average LGAG was 55 ± 2 nm, 29 ± 1 nm and 33 ± 1 nm, respectively.  
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Figure 3-1: AFM height images of newborn (first row), 29-year-old (second row) and 38-
year-old (third row) human aggrecan. Globular domains are indicated by arrows in (b), (e) 
and (h). (c), (f) and (i) are representative images of full-length aggrecan which have 
globular domains at both ends. Example of core protein trace, indicated by LCP and GAG 
chain trace, indicated by LGAG are shown in (c). 
 43
 
Figure 3-2: Histograms of core protein trace length LCP of all observed aggrecan (left 
column) and full-length aggrecan alone (right column). The entire population of adult 
aggrecan (c) and (e) has smaller mean LCP than that of newborn aggrecan due to the more 
abundant short fragments (<200nm). The histograms of full-length aggrecan alone (with 
G1 and G3 domains identified) have narrower distribution than that of the corresponding 
whole population. The full-length newborn aggrecan LCP (b) is longer than the full-length 
adult aggrecan LCP (d)(f).  
3.3.2.  Full-Length Aggrecan Structural Dimension  
Full-length aggrecan with distinct globular domains identified at both N- and C- terminus 
(Figure 3-1c,f,i) were measured to assess the dimensions of aggrecan before the onset of 
proteolytic cleavage. The LCP and LGAG distributions of full-length aggrecan are shown in 
Figure 3-2 and Figure 3-3 (right column), respectively. The LCP of the full-length 
aggrecan was found to be 547 ± 9 nm for newborn, 474 ± 13 nm for the 29-year-old, and 
498 ± 6 nm for the 38-year-old. The LGAG of full length newborn, 29-year-old and 38-
year-old aggrecan was 56 ± 3 nm, 32 ± 2 nm and 34 ± 2 nm, respectively.  
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Figure 3-3: Histograms of GAG chain trace length LGAG of all observed aggrecan (left 
column) and full-length aggrecan alone (right column). The mean of all observed 
newborn aggrecan (a) is greater than the all observed adult aggrecan (c) and (e). Same 
trend is observed in the full-length aggrecan (b), (d), and (f). The difference in mean was 
not significant between all observed aggrecan and the corresponding full-length aggrecan. 
3.3.3.  Keratanase and Chondroitinase Treated Aggrecan 
The 29-year-old human aggrecan was treated with Keratanase II or Chondroitinase ABC 
in order to remove the CS or KS GAG chains, respectively. The KS-digested aggrecan 
appeared globally similar to the untreated aggrecan (Figure 3-4a,b). The remaining CS 
GAG chains of the KS-digested aggrecan correspond to the predominant GAG chains in 
the untreated aggrecan. The CS-digested aggrecan was observed to have a relatively long, 
GAG-free region of core protein (Figure 3-4), corresponding to the position of the CS1 
and CS2 domains, which occupy ~70% of the total aggrecan contour length. However, 
shorter GAG chains were still visible located nearer to the globular G1-G2 domains, 
corresponding to one of the putative locations of KS (Figure 3-4d,e). The LCP 
distributions of the full-length KS-digested and CS-digested aggrecan are shown in 
Figure 3-5 with smaller means of 407 ± 16 nm and 331 ± 9 nm, respectively, than the 
untreated full-length aggrecan.  
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Figure 3-4: Typical AFM height images of (a) untreated, (b) keratanase II-treated and (c) 
chondroitinase ABC-treated 29-year-old aggrecan. (d)(e) Higher-magnification images of 
chondroitinase ABC-treated aggrecan. Some short GAG chains (indicated by arrows), 
presumably KS, are visualized near one end of the core protein.  
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Figure 3-5: Representative images of full-length (a) keratanase II-treated aggrecan and (b) 
chondroitinase ABC-treated aggrecan. The LCP distributions of (c) full-length keratanase 
II-treated aggrecan and (d) full-length chondroitinase ABC-treated aggrecan show peaks 
shifted to the left with respect to the untreated full-length aggrecan (dotted line, from 
Figure 3-2d). 
3.3.4.  Core Protein Persistence Length 
The 2D effective persistence length LP, which represents the stiffness of the molecules, 
was calculated with the worm-like-chain model for the full-length aggrecan of all 
samples. For the untreated newborn, 29-year-old and 38-year-old full-length aggrecan, 
the LP was 335 ± 25, 104 ± 28 nm, and 165 ± 11, respectively. The LP of the enzyme-
treated full-length aggrecan were 86 ± 13 nm and 94± 9 nm for the keratanase II-treated 
and the chondroitinase ABC-treated, respectively. 
3.4 Discussion 
We have demonstrated the direct visualization of single molecule aggrecan with 
resolution of individual GAG chains. The structural dimensions of aggrecan from donors 
of different ages were quantified. Through direct visualization, specific populations can 
be selectively measured from the images. For example, the full-length aggrecan 
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population which represents the newly synthesized aggrecan population was separately 
examined and characterized for the age-related structural variations independent of 
proteolytic degradation effects. Further more, the constituent CS or KS GAG chains were 
selectively removed in order to observe the effect of GAG chains on the morphology of 
aggrecan core protein.  
The age-related changes of aggrecan structure can be ascribed to either biosynthetic 
or proteolytic variations. Biosynthesis of post-translational glycosylation is a major factor 
in determining size and composition of the aggrecan [38-42]. Decrease in the size and 
number of CS as well as increase in the size and number of KS chains found in the adult 
aggrecan population [21,35,43,44] could result from variations in biosynthesis. 
Progressive proteolytic cleavage of the core protein, on the other hand, would also 
change the structure of the aggrecan [8,9,45]. Aggrecan cleaved within CS2 domains 
loses part of its CS enriched region and hence results in an increased KS/CS ratio and 
decreased molecular weight. In the obtained AFM height images, both biosynthetic and 
proteolytic effects on the aggrecan structure were observed. Small aggrecan fragments in 
newborn and adult aggrecan populations indicate the progressive proteolytic process. In 
the adult aggrecan populations, there were relatively more small fragments (<200 nm) 
showing the accumulation of G1-containing fragments with increasing age. The shorter 
GAG chain length in the adult aggrecan population reflected the biosynthetic variations. 
The combination of proteolytic degradation and biosynthetic alteration results in an 
increased heterogeneity in the adult populations. 
With the advantages of direct visualization, we specifically picked the full-length 
aggrecan subpopulation which had globular domains identified at N- and C-termini. The 
full length aggrecan has not been cleaved by proteolytic enzymes and hence should only 
reflect the biosynthetic variation. Moreover, the full-length aggrecan’s half life time is 
~3.4 years [46] which means that the full-length aggrecan represents the newly-
synthesized population around the donors’ present ages. Therefore, the biosynthetic 
alterations observed on the full-length adult aggrecan are most likely due to aging. The 
structural changes found on the full-length adult aggrecan include shorter LCP and LGAG. 
The decreased LGAG with age is consistent with the findings of decreased CS chain length, 
increased KS length and ratio of KS/CS with age [21]. However, the exact mechanisms 
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of GAG chain termination and substitution are still under study. The decrease in LCP of 
full-length core protein with age has not been reported by biochemical studies due to the 
limitation of the methodologies. The hydrodynamic size of aggrecan is known to 
decrease with age, but the technique can not separately examine the full-length aggrecan 
and even if it could, the measure would not be able to differentiate the changes in LCP and 
LGAG. The reason for the decreased LCP (i.e., decrease in the apparent core protein length) 
in adult full-length aggrecan is less obvious because the amino acid sequence of the full-
length core protein should be conserved, except for some small variations in the CS1 
domain [47-49]. This significant decrease in LCP may reflect a less extended GAG-
attachment region in the presence of shorter GAG chains in the adult aggrecan. As 
opposed to the adult aggrecan, the longer GAG chains on the newborn may generate 
greater inter-molecular electrostatic repulsion and thus extend the core protein to a larger 
apparent length. 
The effect of GAG on core protein apparent length (trace length LCP) was further 
studied by examining the deglycosylated core protein. The average LCP of the full-length 
aggrecan (29-year-old) decreased 14% after Keratanase II treatment and 28% after 
Chondroitinase ABC treatment. The reduction in LCP of deglycosylated core protein is 
consistent with the hypothesis that the core protein is extended by the present GAG 
chains. Moreover, the degree of extension depends on the length and number of GAG 
chains. The length and number of GAG chains could also be the determinants for the core 
protein persistence length LP. Newborn aggrecan which has the longest GAG chains 
exhibited greatest LP, whereas the adult aggrecan showed decreased LP, possibly due to 
the reduced intra-molecular repulsion and steric effects of shorter GAG chains. The GAG 
digested aggrecan, also showed decreased LP. In particular, the chondroitin ABC-treated 
aggrecan which had the predominant CS GAG chains removed had the lowest LP and 
may closely represent the initial LCP and LP of bare core protein. 
Although AFM imaging techniques are useful for defining the structure of individual 
aggrecan, they cannot determine molecular composition. At this point, we observed the 
change in GAG length, but we were not able to identify whether the GAG chain was KS 
or CS, especially in the adult sample where KS and CS length were presumably closer. It 
is also difficult to determine the cleavage sites of the fragments which have lost their G3 
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terminals. However, these limitations will hopefully be resolved by combining the AFM 
imaging techniques with biochemical techniques. For example, we have demonstrated 
using chondroitinase or keratanase to digest aggrecan monomers [50] in order to visualize 
the KS or CS chains separately and further confirm their length, number, and location 
along the core protein. Antibody binding techniques may also help to identify the 
cleavage sites or the G3 domains [8,28]. In summary, the results of the present study 
support previous biochemical studies on age-related trends in aggrecan structure, but also 
extend these bulk observations to the individual molecular level, allowing changes due to 
synthesis to be distinguished from those due to degradation.  
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Chapter 4  
Intra- and Inter-molecular Structure 
of Aggrecan Aggregates 
4.1 Introduction 
Hierarchical self-assembly structures are ubiquitous in animal tissues such as bone, 
cartilage, muscle and intestine. The macromolecular building blocks are constructed into 
a particular architecture with specific mechanical properties for a unique function. One 
example is the aggrecan aggregate in cartilage extracellular matrix. The bottle-brush 
shaped aggrecan macromolecule is comprised of a protein backbone and ~100 
glycosaminoglycan (GAG) side chains (chondroitin sulfate (CS) and keratan sulfate 
(KS)), which are linear polymers of negatively charged repeating disaccharides (Figure 4-
1a). In the presence of hyaluronic acid (HA) and link protein (LP) under physiological 
conditions, multiple aggrecan monomers self-assemble and noncovalently bind to HA 
through their G1 N-terminal domains with LP further stabilizing the binding (Figure 4-
1a). This secondary structure of aggregated aggrecan monomers along the central 
filament HA is thought to be responsible for preventing aggrecan monomers from 
diffusing out of the ECM. 
Aggrecan monomers and HA-aggrecan aggregates have distinct solution structures 
and behavior. At physiological aggrecan concentrations, formation of HA-aggrecan 
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aggregates increases the osmotic pressure and viscosity of the aggrecan solution [51,52]. 
Dynamic light, neutron and x-ray scattering measurements showed that the HA-aggrecan 
aggregates behave like microgels and the individual aggrecan in the microgels retain their 
identity with little interpenetration among the aggrecan subunits [51]. The aggregate 
solutions exhibit predominantly elastic response and pronounced shear-thinning behavior; 
whereas the monomer solutions exhibit primarily viscous and Newtonian flow behavior 
[53,54]. Reduction in HA size can abolish the elastic network of the aggrecan-HA 
complex [55].  
The characteristics of aggrecan aggregate solutions are highly associated with its 
hierarchical structure. The spatial organization and conformation of aggregates can alter 
their charge density and molecular interaction. Detailed structural information of 
aggrecan aggregates is essential to elucidate the structure-property relationship of 
aggrecan aggregates. Direct visualization via electron microscopy (EM) or atomic force 
microscopy (AFM) aids in characterizing the spatial structure of aggrecan aggregates. 
EM studies of in vitro reassembled aggrecan aggregates showed cooperative binding 
mechanisms, as opposed to random binding, when LP was present [56]. The closest 
centre-to-centre distance found between adjacent G1 domains was 12 nm [30]. AFM can 
additionally enable high resolution and direct visualization of individual macromolecular 
constituents of aggregates, i.e., individual GAG [4] and HA [57] and important 
information, such as intra-molecular heterogeneity that can not be assessed via traditional 
biochemical methods. 
In this present study, aggrecan aggregates of different packing densities were 
reconstituted in vitro with purified and characterized cartilage extracellular matrix (ECM) 
components (ie. aggrecan, HA, and LP). The ECM components and aggregates thereof 
were imaged using recently developed high resolution AFM methods [4]. The 
ultrastructure, conformation, and intermolecular binding within individual aggregates 
were directly visualized and quantified for relevant structural parameters (e.g., aggrecan 
areal density, extension ratio, and flexibility). The results provide insights into the 
mechanisms of self-assembly and intermolecular interactions that may occur in vivo. 
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Figure 4-1: (a) Hierarchical structure of aggrecan aggregates. The repeating disaccharide 
units: keratan sulfate (KS), chondroitin sulfate (CS) and hyaluronan (HA) are the 
building blocks of three types of glycosaminoglycan (GAG) chains. About 30 KS and 
100 CS GAG chains are attached to the aggrecan core protein (CP). The G1 domain of 
CP mediates the binding to HA chains. Link protein (LP), which has a homologous 
structure of G1, can further stabilize the binding of G1 to HA. G2 shares a homologous 
sequence with G1, but lacks ability to bind to HA. The CP is terminated by the C-
terminal globular domain G3. The arrangement of G1 and link protein in the HA central 
filament is hypothetical. (b) An AFM image of SelectHA and the trace length distribution 
of SelectHA. SelectHA exhibits an extended conformation with little overlapping or 
coiling on the surface. (c) Elution profiles of aggrecan monomers and aggregates on a 
S1000 Sephacryl chromatography column. The aggrecan monomer alone (red thin line) 
appeared as a single species with Kav ~0.32. With addition of HA and LP, the monomer 
amount decreased and a higher molecular weight (Kav ~0) species formed, indicating the 
aggregation of aggrecan (blue and green lines). 
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4.2 Materials and Methods 
4.2.1.  Preparation of Aggrecan, LP, HA and Aggregates Thereof 
Aggrecan monomers were extracted from fetal bovine epiphyseal growth plate as 
previously described [4]. The tissue was diced and extracted in 4M guanidium 
hydrochloride, 100 mM sodium acetate, pH 7.0, with protease inhibitors for 48 hrs. Link 
protein from calf cartilage was extracted the same way. Aggrecan and link protein were 
purified by a series of cesium gradient centrifugations (A1A1D1D1 and A1A1D5, 
respectively), dialyzed consecutively against 500 volumes of 1M NaCl and deionized 
water and stored in -80°C.  The high molecular weight HA, Healon (~4 MDa, Pharmacia, 
Stockholm, Sweden) was prepared from rooster comb). The low molecular weight HA, 
SelectHA (200-300 KDa, Hyalose, Oklahoma City, OK), wad made via enzymatic 
synthesis. Aggregates were reconstituted in vitro by combining 100 µg aggrecan 
monomers with 0.4–0.8 % (w/w) of HA and 0.2% (w/w) link protein in 50 µl deionized 
(DI) water at 4°C for at least 8 hrs. 
4.2.2.  Size Exclusion Chromatography 
The aggregate samples were fractionated via S1000 Sephacryl column chromatography 
(GE Healthcare, Piscataway, NJ) and eluted at 30 ml/hr with 0.5M sodium acetate at pH 
6.8. Fractions (0.5 ml) were collected and analyzed using the dimethylmethylene blue 
assay for aggrecan (sulfated GAG) concentration. The void volume (Kav = 0) and total 
volume (Kav = 1) were determined using DNA (10-15 MDa, Sigma-Aldrich, St. Louis, 
MO) and phenol red (100 kDa, Sigma-Aldrich), respectively. 
4.2.3.  AFM Sample Preparation and Imaging 
The high molecular weight fractions (>10MDa) containing aggrecan aggregates were 
diluted 100 times with DI water to 0.005M IS and to ~0.1 µg/ml aggrecan for AFM 
imaging. The diluted sample (50 µl) was dropped onto an aminopropyltriethoxysilane-
modified mica substrate (1 cm × 1 cm, SPI Supplies, West Chester, PA), incubated for ~4 
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hrs, rinsed with DI water and air dried. Monolayers of isolated aggrecan monomers were 
prepared with 50 µg/ml aggrecan monomer solution and 20 minutes incubation time. 
Dense monolayers of aggrecan monomers were prepared with 500 µg/ml aggrecan 
monomer solution and 20–30 minutes incubation time. AFM height images were 
obtained by tapping mode in ambient conditions (probe tip spring constant ≈ 45 N/m, tip 
end radius<10 nm). About 10–20 images, 3 µm × 3 µm in size were taken at different 
locations on the substrate of multiple samples for analysis. The profiles of the aggrecan 
core protein were manually traced and digitized using commercial software (SigmaScan 
Pro5, Aspire Software International, Ashburn, VA) for core protein conformation 
analysis. 
4.3 Results 
4.3.1.  Length Distribution of SelectHA 
Aggrecan aggregates were reconstituted with aggrecan monomers extracted from fetal 
bovine epiphyseal cartilage, LP extracted from calf cartilage and two sizes of HA, Healon 
(4MDa, prepared from rooster comb) and SelectHA (250 kDa ≈ 600 disaccharides, 
prepared from in vitro synthesis). The size of these ECM components had been 
characterized previously via AFM or EM imaging techniques [4,30,57] except for 
SelectHA. Therefore, we analyzed the length distribution of SelectHA with AFM 
imaging and observed a normal distribution with a single peak at 537 nm (Figure 4-1b), 
consistent with the estimated length 542 nm (1 disaccharides ≈ 0.9 nm).  
4.3.2.  Chromatography Profiles of Reconstituted Aggregates 
The hydrodynamic size distribution of aggrecan monomers alone and aggrecan in the 
presence of HA and LP were characterized by size exclusion chromatography (Figure 4-
1c). Aggrecan monomers alone have a normal distribution (peak at partition coefficient 
Kav ≈ 0.32) whereas in the presence of HA and LP, they have a bimodal distribution − a 
second peak with increased molecular weight (Kav = 0). The appearance of the large 
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molecular weight complex indicated the formation of aggrecan aggregates. Both types of 
HA formed aggregates with aggrecan. The higher ratio of HA to aggrecan (0.8 % w/w 
Healon) increases the proportion of aggregates in the solution. 
4.3.3.  AFM Imaging of Reconstituted Aggregates 
The high-molecular-weight complexes were imaged via AFM and the formation of 
SelectHA-aggrecan and Healon-aggrecan aggregates were visually confirmed (Figure 4-
2). The observed SelectHA-aggrecan aggregates (Figure 4-2a) were composed of 3 to 13 
aggrecan per aggregate, corresponding to a relatively compact conformation with the 
aggrecan linear density on HA (5–25 aggrecan/µm). The number of aggrecan monomers 
per observed Healon-aggrecan aggregate (Figure 4-2b) ranged from 3 to 21, 
corresponding to a relatively sparse packing density (0.3–2 aggrecan/µm). It is 
noteworthy that the aggrecan monomers in the aggregates lay on the surface in a flat 
fashion and exhibited noticeable flexibility (quantified later in Figure 4-4) to conform to 
the neighboring aggrecan with little overlap even at the high local surface packing 
density. 
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Figure 4-2: Reconstituted aggrecan aggregates visualized and quantified via AFM. (a) 
SelectHA-aggrecan aggregates and (b) Healon-aggrecan aggregates were adsorbed on 
APTES-mica substrate and imaged with AFM. The observed aggregates were quantified 
for the number of aggrecan per aggregate. The corresponding linear density of aggrecan 
aggregates was defined as the number of aggrecan per aggregate divided by the average 
length of HA (SelectHA ≈ 537 nm and Healon ≈ 8600 nm). n = number of measured 
aggregates. 
4.3.4.  Intermolecular Binding 
At higher magnification, the binding interactions between HA and aggrecan could be 
resolved (Figure 4-3a,b). The HA was seen tethering multiple aggrecan molecules 
through the aggrecan G1 domains (Figure 4-3a, circled region). Binding structures with 
stabilization of LP were also observed (Figure 4-3b). The LP appeared as a similarly 
sized globe as compared to the G1 domain (diameter ~ 15 nm) and was located directly 
adjacent to the G1 domain along the HA. The observed HA-G1-LP organization 
confirmed the ternary structure model proposed [30], but had not been previously 
resolved for G1 or LP.  
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Figure 4-3: Detailed aggregate intermolecular binding structure and core protein 
intramolecular flexibility. (a) Aggrecan binds to SelectHA through its G1 domain (circled 
region) without LP. (b) The aggrecan-LP-HA ternary binding structure is visualized. LP 
is located right next to the aggrecan G1 domain to stabilize the binding between HA and 
aggrecan. (c) An example of HA-bound aggrecan with increased core protein flexibility 
near the G1 domain. 
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4.3.5.  Core Protein Intramolecular Flexibility 
The N-terminal regions (the less glycosylated G1-G2 domains) of HA-bound aggrecan 
core protein were observed with increased flexibility in many AFM images. An example 
of HA-bound aggrecan with this distinct feature was traced for the core protein profile 
and analyzed for the curvature (Figure 4-3c). The IGD and KS domains exhibited larger 
maximum curvatures than the CS domains. The function of the increased flexibility in the 
N-terminal regions will be discussed in the Discussion section. 
4.3.6.  Effects of HA-binding and Surface Density on Aggrecan 
Core Protein Extension Ratio 
In order to examine the effect of HA-binding and packing density on aggrecan 
conformation, we observed the morphology of aggrecan in four different conditions: 
isolated monomer, loosely packed aggregate, densely packed aggregate and dense 
monolayer of monomers (Figure 4-4a). The conformation of the aggrecan was quantified 
by the extension ratio of the core protein defined as the end-to-end distance (Ree) divided 
by the trace length of the core protein (LCP). For the aggregated aggrecan in the same 
aggregate, their extension ratios were averaged and plotted versus the areal density of the 
aggregate, which is the number of aggrecan in the aggregate divided by the area occupied 
by the aggregate. For the unaggregated aggrecan monomers in the same uniform 
monolayer, their extension ratios were averaged and plotted versus the aggrecan areal 
density of the monolayer. The core protein extension ratio was found to decrease with 
increasing aggrecan areal density for both aggregated and unaggregated aggrecan (Figure 
4-4b). The binding of HA showed little effect on the extension ratio of aggrecan when 
compared with the aggregated aggrecan with the unaggregated monomers at similar areal 
densities. However, HA-bound aggrecan had a preferred orientation with the G1 domains 
pointing toward the HA central filament. Binding to HA also created localized high 
aggrecan areal density as oppose to a uniform monolayer of aggrecan monomers. 
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Figure 4-4: Effect of density and HA binding on aggrecan conformation quantified via 
extension ratio. (a) Representative images of aggrecan in 4 states: isolated monomer, 
sparse aggregate, dense aggregate, dense monomer. (b) Aggrecan core protein extension 
ratio versus aggrecan areal density. Each data point represents the mean of the aggrecan 
core extension ratios for a given aggregate or monolayer of monomers. The standard 
deviations of the extension ratio are less than 0.15. The linear fit has a significant 
negative slope (95% confidence interval: -0.015 ~ -0.006). 
4.4 Discussion 
Two types of aggrecan aggregates were formed with different molecular weight of HA – 
SelectHA and Healon. Based on the hypothesis that the minimum spacing between 
adjacent monomers on a nearly saturated HA chain is ~30-60 disaccharide units [10,58], 
the maximum number of aggrecan per HA is estimated to be 10-20 for SelectHA and 
160-320 for Healon. The observed SelectHA-aggrecan aggregates were close to their 
maximum packing density, whereas the observed Healon-aggrecan aggregates were far 
below their maximum packing density. The calculated linear density of the SelectHA-
aggrecan aggregates is about 10 times larger than the Healon-aggrecan aggregates. The 
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difference in the linear density was not likely due to the length of HA nor the mixing 
ratio. The molar ratios of HA and aggrecan in the initial solution were 1:20 for SelectHA-
aggrecan and 1:160 for Healon-aggrecan. Theoretically, there were enough aggrecan in 
the solution for both types of HA to form aggregates of maximum density. The reason 
why the observed Healon-aggrecan aggregates had low packing densities may be due to 
the effects of diffusion during the sample preparation. The lower packing density (lower 
molecular weight) aggregates diffused faster (t ~ x2/D, D: diffusion coefficient, 
proportional to the hydrodynamic size of the aggregate) toward the substrate and thus 
were adsorbed earlier than the higher packing density aggregates. The diffusion effect is 
less pronounced for the SelectHA-aggrecan aggregates because the aggregate size 
variation within the SelectHA-aggrecan population is not as large as that in the Healon-
aggrecan aggregate population. 
The core protein of aggrecan was found to have increasing flexibility in the IGD and 
KS regions. These two regions have fewer and shorter substituted GAG chains [59] (i.e., 
less intramolecular steric force and electrostatic repulsion) and thus may allow more 
bending when needed. Similar results were observed when the core protein was 
deglycosylated (Chapter 3). The deglycosylated core protein has a decreased persistence 
length indicating a decrease in core protein bending stiffness (i.e., increase in flexibility). 
For intact aggrecan, the increased flexibility near the G1 domain, the HA binding domain, 
may be important during the aggregate self-assembly process. With the flexible core 
protein region near the G1 domain, the anchored aggrecan on the HA could have more 
freedom to create a larger space for the next aggrecan to bind and to pack as closely as 
possible. 
The whole core protein also showed its flexibility to accommodate the adjacent 
molecules at high aggrecan surface density. The curved conformation (low Ree) of the 
aggrecan core protein resulted in a decreased extension ratio at high aggrecan areal 
density. In vivo, the aggrecan concentration is about 20–80 mg/ml [3] and increases upon 
compression. The conformation of the aggrecan in vivo, such as the radius of gyration, 
would decrease with increasing density. Binding to HA had little effect on the extension 
ratio, but oriented aggrecan in a preferred direction and created localized aggrecan 
clusters. 
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Taken together, we have directly visualized the formation of aggrecan aggregates 
and confirmed the ternary structure formed by HA, aggrecan G1 domains, and link 
protein. We observed an increased flexibility in the IGD and KS domains near the N-
terminal HA binding region, which may have important functions during the aggregate 
self-assembly process. We also demonstrated that the extension ratio of aggrecan 
decreased with increasing aggrecan areal density. HA increased the local aggrecan 
density and organized aggrecan with a preferred orientation. The findings on intra-
molecular structures and inter-molecular interaction may be important determinants of 
aggrecan physical properties and could provide some insight into the structure-properties 
of aggrecan aggregates and the aggregation process occurring in vivo. 
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Chapter 5  
Adult Equine Bone Marrow Stromal 
Cells Produce a Cartilage-like ECM 
Mechanically Superior to Animal-
matched Adult Chondrocytes 
This chapter was published as a paper in Tissue Engineering: Part A in 2010 [60]. 
Additional data of FACE analysis is included in Appendix B. 
5.1 Introduction 
Because of their capacity to undergo chondrogenesis [61-63], bone-marrow derived 
stromal cells (BMSCs) have been the focus of numerous studies with the ultimate goal of 
repairing cartilage tissue damaged through disease or injury [64-66]. Recent reports have 
suggested a robust chondrogenic and tissue forming capacity for BMSCs that is sustained 
with aging [65,67-69], in contrast with primary chondrocytes which have decreased 
matrix synthesis and tissue repair potential with age [70-73]. This age-related behavior is 
particularly important given the potential advantages of using autologous tissue for 
cartilage repair [74,75] making BMSCs an attractive candidate cell source. 
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Several recent studies have focused on encapsulation of BMSCs in 3D hydrogel 
culture with TGF-β1 or TGF-β3 stimulation to induce chondrogenesis and compared the 
differentiated cell phenotype with that of primary chondrocytes [65,66,76]. While these 
studies showed that chondrocytes produce a more cartilage-like and mechanically-
functional extracellular matrix (ECM) than BMSCs, they all used skeletally-immature 
bovine tissue as the source for both cell types. Given that the relative chondrogenic 
potential of chondrocytes vs. BMSCs changes with age, evaluation of chondrocyte- and 
BMSC-seeded hydrogels at multiple times during development and aging is important. 
To achieve cartilage repair, a successful cell-based strategy will be required to 
recapitulate the fine structure of the native cartilage ECM in order to produce a 
mechanically functional tissue. Aggrecan, a large aggregating proteoglycan, is the 
primary cartilage ECM molecule that provides the compressive stiffness and load 
distribution functions of the tissue [13]. Given the extensive changes in aggrecan 
biosynthesis [77,78], processing [31,35], aggregation [71] and degradation [13] with age, 
it will likely be important to evaluate the quality of aggrecan produced by any cell type 
used in a cartilage repair therapy. Numerous techniques exist for the study of aggrecan 
including chromatography [79] and Western analysis [80], which assess size distribution 
and cleavage products in an entire population of molecules, and imaging techniques such 
as electron microscopy [28] and atomic force microscopy (AFM; [4]), which allow for 
detailed measurements of individual molecules.  
In this study, we hypothesized that adult BMSCs could produce mechanically-
functional cartilage-like neo-tissue comparable to that of primary chondrocytes derived 
from animal-matched donors. Furthermore we hypothesized that neo-tissue quality for 
BMSC vs. chondrocyte cell sources would depend on the age of the animal donor. To test 
these hypotheses, equine bone marrow and cartilage tissue were both harvested from 
immature foal and skeletally-mature young-adult horses. BMSCs and chondrocytes were 
isolated and encapsulated in a self-assembling peptide hydrogel that has been shown to 
enhance TGF-β1 stimulated chondrogenesis of BMSCs and promote accumulation of an 
aggrecan and type II collagen rich neo-ECM [64,81]. These peptides are being developed 
for use in cardiovascular [82,83], liver [84], and cartilage [85] repair, and have been 
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successfully used in animal studies without inducing inflammation or immune response 
[82,83], making them candidate in vivo tissue engineering scaffolds.  
Using dynamic compression testing, we measured the neo-tissue mechanical 
phenotype produced by BMSCs and chondrocytes from both young and adult animal 
sources after 21 days of culture. To understand the mechanisms which generate this 
mechanical phenotype, we quantitatively measured cellular content and ECM synthesis 
and accumulation. To further assess the quality of the ECM, proteoglycans were 
extracted and characterized by size exclusion chromatography to examine the size 
distribution of proteoglycan monomers. Proteoglycan extracts were also purified and 
imaged by single molecule AFM to enable detailed ultrastructural studies of individual 
aggrecan molecules. 
5.2 Materials and Methods 
5.2.1.  Materials 
KLD12 peptide with the sequence AcN-(KLDL)3-CNH2 was synthesized by the MIT 
Biopolymers Laboratory (Cambridge, MA) using an ABI Model 433A peptide 
synthesizer with FMOC protection. All other materials were purchased from the suppliers 
noted below. 
5.2.2.  Tissue Harvest 
Cartilage tissue was harvested aseptically from the femoropatellar groove, and bone 
marrow was harvested from the sternum and iliac crest of two immature (2-4 month-old 
foals) and three skeletally-mature (2-5 year-old adults) mixed-breed horses as described 
previously [64]. Horses were euthanized at Colorado State University for reasons 
unrelated to conditions that would affect either tissue. Bone marrow and cartilage tissue 
samples were both harvested from each animal and were processed as animal-matched 
specimens. 
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5.2.3.  Cell Isolation 
Chondrocytes were isolated by sequential pronase (Sigma-Aldrich, St. Louis, MO), 
collagenase (Roche Applied Science, Indianapolis, IN) digestion as described previously 
[86]. Marrow samples were washed in PBS and fractionated by centrifugation to remove 
red blood cells.  BMSCs were isolated from the remaining nucleated cell pellet by 
differential adhesion as described previously [64]. After BMSC colonies reached local 
confluence, cells were detached with 0.05% trypsin/1mM EDTA (Invitrogen), reseeded 
at 6x103 cells/cm2, expanded to ~70% confluence, and cryo-preserved in liquid nitrogen. 
Prior to peptide hydrogel encapsulation, BMSCs were thawed and plated at 6x103 
cells/cm2 in low glucose DMEM plus 10% ES-FBS (embryonic stem cell qualified fetal 
bovine serum, Invitrogen Carlsbad, CA), 10mM HEPES, and PSA (100 U/mL penicillin, 
100 μg/mL streptomycin, and 250 ng/mL amphotericin) plus 5 ng/mL bFGF (R&D 
Systems, Minneapolis, MN). After 3 days, cells were detached with 0.05% trypsin/1mM 
EDTA at ~3x104 cells/cm2 (passage 1) and reseeded at 6x103 cells/cm2. Over the 
subsequent 3 days, this expansion was repeated for passage 2 after which cells were 
detached for encapsulation in peptide hydrogels. 
5.2.4.  Hydrogel Encapsulation and Culture 
BMSCs and chondrocytes were encapsulated in 0.35% (w/v) KLD12 peptide at a 
concentration of 10x106 cells/mL using acellular agarose casting molds to initiate peptide 
assembly as described previously [81]. Hydrogel disks with an initial volume of 50 μL 
and dimensions of 6.35 mm diameter by 1.57 mm thick, were cultured in high glucose 
DMEM (Invitrogen) supplemented with 1% ITS+1 (final concentration: 10 μg/ml insulin, 
5.5 μg/ml transferrin, 5 ng/ml sodium selenite, 0.5 mg/ml bovine serum albumin, 4.7 
μg/ml linoleic acid, Sigma-Aldrich), 0.1 μM dexamethasone (Sigma-Aldrich), 37.5 
μg/mL ascorbate-2-phosphate (Wako Chemicals, Richmond, VA), 1% PSA, 10mM 
HEPES, 400μM L-proline, 1mM sodium pyruvate, and 1% NEAA, with (+TGF) or 
without (Cntl) 10 ng/mL recombinant human TGF-β1 (R&D Systems) with medium 
changes every 2-3 days. For all assays except cell viability, hydrogels were cultured for 
21 days. 
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5.2.5.  Cell Viability 
One day after encapsulation, selected specimens from each treatment group of cell-
seeded-peptide hydrogels were stained with 350 ng/mL ethidium bromide (dead) and 
12.5 μg/mL fluorescein diacetate (live) in PBS and imaged with a Nikon Eclipse 
fluorescent microscope. The total number of live and dead cells from each of three fields 
were counted for each animal and % viability was calculated as the number of live cells 
divided by total number of cells (live + dead). 
5.2.6.  Mechanical Stiffness 
After 21 days of culture, hydrogels were placed in PBS with protease inhibitors (Protease 
Complete, Roche) and a digital image was captured from which plug cross-sectional area 
was measured with the Matlab Image Processing Toolbox (The MathWorks, Natick, MA). 
For each cell type and medium condition, 6-9 hydrogel disks were tested (3 gels per 
animal x 2-3 animals). The dynamic stiffness of each plug was measured in uniaxial 
unconfined compression using a Dynastat mechanical spectrometer (IMASS, Hingham, 
MA) as described [87]. A 15% offset compression was first applied via three sequential 
5% ramp-and-hold steps (5% strain applied over 60 seconds, followed by 4-minute hold), 
followed by a frequency sweep of 0.5% displacement amplitude sinusoidal strains at 0.05, 
0.1, 0.3, 0.5, 1.0, and 5.0 Hz. The dynamic compressive stiffness at each frequency was 
calculated as the ratio of the fundamental amplitudes of stress to strain [87]. Note no 
mechanical testing data was recorded for adult BMSCs cultured in TGF-β1-free medium. 
5.2.7.  DNA Content and ECM Biochemistry 
On day 20 of culture, medium was additionally supplemented with 5 μCi/mL of 35S-
sulfate and 10 μCi/mL of 3H-proline to measure cellular biosynthesis of proteoglycans 
and proteins, respectively. At day 21, hydrogels were rinsed 4x30 minutes in PBS with 
excess unlabeled sulfate and proline to remove free label. Hydrogels were weighed wet, 
lyophilized, weighed dry, and digested in 250 μg/mL proteinase-K (Roche) overnight at 
60ºC. Digested samples were assayed for total DNA content by Hoechst dye binding [88], 
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retained sulfated glycosaminoglycan (sGAG) content by DMMB dye binding assay [89], 
hydroxyproline(OH-Proline) content by chloramine T and p-dimethylaminobenzaldehyde 
reaction [90], and radiolabel incorporation with a liquid scintillation counter 
(PerkinElmer 1450 MicroBeta TriLux). Conditioned culture medium collected 
throughout the study was also analyzed for sGAG content by DMMB dye binding. 
5.2.8.  Proteoglycan Size-exclusion Chromatography 
For the final 24 hours, another group of hydrogel specimens from each animal was 
cultured in medium supplemented with 50 μCi/mL of 35S-sulfate. Proteins were 
extracted from the minced sample with 4M guanidine HCl and 100mM sodium acetate 
with protease inhibitors (Protease Complete, Roche) for 48 hours at 4ºC with agitation 
[35]. Extracts were desalted with a Sephadex G-50 column (GE Healthcare Bio-Sciences, 
Piscataway, NJ), lyophilized and resuspended in 500mM ammonium acetate for 
separation on a Superose 6 column (GE Healthcare Bio-Sciences). 35S-sulfate labeled 
proteoglycans were detected via an inline liquid scintillation counter (Packard 
Radiomatic Series A-500). For native cartilage tissue extracts, 0.5mL fractions were 
collected and unlabeled proteoglycans were detected via DMMB dye binding. 
5.2.9.  Aggrecan Monomer Extraction and AFM Sample 
Preparation 
Proteins were extracted from separate unlabeled, day 21 hydrogel specimens from 3 adult 
and 2 foal horses with 4M guanidine as above. Extracts were adjusted to a density of 1.58 
g/mL by the addition of CsCl and subjected to density gradient centrifugation at 470 ,000 
gav for 72 hours at 4ºC. The gradient was fractionated and the 10 resulting fractions were 
assayed for density by weighing 80 µL aliquots from each fraction and for sGAG content 
by DMMB dye binding. Fractions were combined according to density with fractions 
>1.54 g/mL (labeled D1) expected to contain most of the proteoglycan content of the 
extract [35]. The D1 fraction was then dialyzed once against 500 volumes of NaCl, and 
exhaustively against water at 4˚C and sGAG content was quantified by DMMB dye 
binding. 
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Aggrecan samples for AFM imaging were prepared as described previously [91]. 
Muscovite mica surfaces (SPI Supplies, West Chester, PA, #1804 V-5) were treated with 
0.01% 3-amino-propyltriethoxysilane (APTES; Sigma Aldrich) v/v in MilliQ water (18 
MΩ · cm resistivity, Purelab Plus UV/UF, US Filter, Lowell, MA). Sixty microliters of 
APTES solution was deposited onto freshly cleaved mica, incubated for 20–30 min at 
room temperature in a humidity controlled environment, rinsed gently with MilliQ water. 
The APTES-modified mica substrate was then incubated for 20-30 min with 50 µL 
aliquots of the purified aggrecan solution (prepared as described above) which was 
diluted to 250 μg/ml final sGAG content in MilliQ filtered water, gently rinsed with 
MilliQ water and air dried. Electrostatic interaction between the APTES-mica and the 
aggrecan sGAG chains enabled retention of a population of aggrecan despite rinsing [91]. 
A thin layer of absorbed water 2–10 Ǻ thick exists on the mica surface in ambient 
conditions [92] which partially binds to and hydrates the hydrophilic aggrecan, helping to 
preserve near physiologic conditions. 
5.2.10.  AFM Imaging 
Imaging was performed as described previously [91]. A Nanoscope IIIa Multimode AFM 
(Digital Instruments (DI), Santa Barbara, CA) was used to image all samples via the EV 
or JV scanners. Tapping mode was employed in ambient temperature and humidity 
conditions using Olympus AC240TS-2 rectangular Si cantilevers (k = 2 N/m). The 
cantilever was driven just below resonant frequency, ω0, and a slow scan rate of 0.5-1 Hz 
was used to minimize sample disturbances giving a scan rate that was much slower 
(<25,000×) than the tap rate. The scans were tested for typical AFM imaging artifacts by 
varying scan direction, scan size, and rotating the sample. The AFM height images were 
digitized into pixels, and the aggrecan structural features were traced automatically with a 
custom Matlab program or manually with SigmaScan Pro image analysis software (SPSS 
Science, Chicago, IL). The aggrecan core protein length and chondroitin sulfate GAG 
(CS-GAG) chain length were each measured using the spatial coordinates of the traces. 
Ten to twenty AFM images, 2 μm × 2µm in size were taken at different locations on the 
substrate of multiple samples for analysis. In each image, all completely scanned 
molecules were measured for the core protein length (3–15 aggrecan per image, total 
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number of measured molecules, n = 100–200).  About 30 randomly-selected aggrecan 
molecules from each group was analyzed for the GAG chain length (number of measured, 
non-intersecting GAG chains per aggrecan = 30–60). 
5.2.11.  Statistical Analysis 
All data are presented as mean ± sem. Data were analyzed using a mixed model of 
variance with animal as a random factor. DNA and ECM data were analyzed with a 3-
factor model (donor age, cell type, TGF-β1 condition) with 4 repeated measurements for 
each donor animal, dynamic stiffness data were analyzed with a 2-factor model 
(frequency and culture condition) with 3 repeated measurements for each donor animal, 
and core-protein and CS-GAG AFM data were analyzed with a 2-factor model (donor 
age and cell type). Residual plots were constructed for dependent variable data to test for 
normality and data were transformed if necessary to satisfy this assumption. Post hoc 
Tukey tests for significance of pairwise comparisons were performed with a threshold for 
significance of p<0.05. 
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5.3 Results 
5.3.1.  Cell Viability 
Both BMSCs and chondrocytes from foal and adult donors survived seeding in peptide 
hydrogels and were >70% viable one day post-encapsulation in the presence of TGF-β1 
(Figure 5-1). Similar viability was observed at day 1 in TGF-β1-free controls; however, 
by day 21, viability in TGF-β1-free controls decreased to 40%-50% for both cell types 
and both donor ages (not shown), consistent with previous studies [93]. 
 
Figure 5-1: Cell viability. Live (green) and dead (red) staining of self-assembling peptide 
hydrogels cultured with TGF-β1 at day 1. 
Foal Chondrocyte Day1 Foal BMSC Day1 
Adult Chondrocyte Day1 Adult BMSC Day1 
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5.3.2.  Mechanical Properties 
Both frequency and culture condition were significant main effects on dynamic stiffness 
(Figure 5-2, p<0.001), and post-hoc pairwise comparisons on each main effect revealed 
significant differences between individual frequencies and between different culture 
conditions. Dynamic stiffness increased monotonically with frequency such that stiffness 
was 29% higher at 5 Hz than at 0.05 Hz (p<0.001). Both adult chondrocyte conditions 
(with and without TGF-β1) were not significantly different than no cell control hydrogels, 
while foal BMSCs and chondrocytes in control medium were 50%-60% higher than 
corresponding frequencies in the no cell controls (p<0.001). Foal chondrocytes with 
TGF-β1 had nearly 4-fold higher dynamic stiffness than no cell controls (p<0.001) and 
2.5-fold higher stiffness than foal chondrocytes in control medium (p<0.001). Both foal 
and adult BMSCs with TGF-β1 supplementation produced neo-tissue with the highest 
dynamic stiffness, ~2-fold higher than the foal chondrocytes with TGF-β1 (p<0.05), and 
were not statistically different from each other. 
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Figure 5-2: Hydrogel dynamic stiffness. Chondrocyte (Chd) and BMSC seeded peptide 
hydrogels after 21 days of culture in control (Cntl) or TGF-β1 supplemented (TGF) 
medium. Stats: mean ± sem, n = 2 foals × 3 samples each or n = 3 adults × 3 samples 
each; ‡ vs. foal chondrocyte TGF, † vs. foal chondrocyte Cntl, # vs. No Cell; p<0.05. 
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5.3.3.  DNA Content 
No significant differences in DNA content were seen between days 0 and 21 for the TGF-
β1-free controls suggesting minimal proliferation under these conditions (Figure 5-3, note 
day 0 DNA content not available for adult BMSCs). In contrast, in the presence of TGF-
β1, BMSC-seeded hydrogels from both foal and adult donors at day 21 had 
approximately 2.5-fold higher DNA content than TGF-β1-free (day 21) controls 
(p<0.001). In addition, chondrocytes from foal donors also proliferated in response to 
TGF-β1, but to a slightly lesser degree than BMSCs, with a 1.6-fold increase in DNA vs. 
TGF-β1-free controls (p<0.001). Chondrocytes isolated from adult donors, however, did 
not proliferate in response to TGF-β1, suggesting a phenotypic distinction (Figure 5-3).  
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Figure 5-3: Hydrogel DNA content.  DNA content for chondrocyte and BMSC hydrogels 
at day 0, or after 21 days. Stats: mean ± sem, n = 2 foals × 4 samples each or n = 3 adults 
× 4 samples each; for a given cell type and age significance is indicated by: # vs. Day 0; * 
vs. Cntl D21; p<0.001. 
5.3.4.  ECM Content and Biosynthesis 
As expected [72], foal chondrocyte-seeded peptide hydrogels accumulated significantly 
higher sGAG per gel than adult chondrocytes both with and without TGF-β1. In the 
absence of TGF-β1, sGAG accumulation per gel was 7-fold higher for foal than for adult 
chondrocytes (Figure 5-4, p<0.001), and with TGF-β1 supplementation, sGAG was more 
than 10-fold higher for the foal compared to adult chondrocyte cultures (p<0.001). 
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Minimal sGAG was produced by BMSCs without TGF-β1 stimulation. However, with 
TGF-β1 supplementation, foal and adult BMSCs accumulated 3-fold and 6-fold higher 
sGAG than adult chondrocytes, respectively (p<0.001). While these day 21 sGAG 
contents for foal and adult BMSCs were a factor of 2-3 lower than foal chondrocyte 
sGAG accumulation, when normalized to wet weight, adult BMSC sGAG was not 
statistically different than foal chondrocyte (Figure 5-4b). This effect is due to 
compaction (defined as the difference between initial and final wet weight divided by the 
initial wet weight) of the peptide hydrogels by BMSCs but not chondrocytes (data not 
shown) consistent with our previous studies [81]. 
Consistent with the sGAG content per gel, foal chondrocyte-seeded peptide 
hydrogels had higher per-cell proteoglycan biosynthesis rates than adult chondrocyte 
hydrogels during the final day of culture (Figure 5-4c, measured by 35S-sulfate 
incorporation normalized to DNA content), although there was only a 2-fold difference 
between foal and adult chondrocytes, both with and without TGF-β1 (p<0.01). 
Proteoglycan biosynthesis in BMSC-seeded peptide hydrogels was minimal without 
TGF-β1 stimulation, but approached the level of foal chondrocytes in the presence of 
TGF-β1 with foal BMSC cultures only a factor of 2 lower (p<0.001) and adult BMSC 
statistically equivalent to foal chondrocyte hydrogels. 
In the presence of TGF-β1, the fraction of sGAG retained vs. the total amount 
produced (retained plus lost to the medium) was highest for foal chondrocytes at 76% 
(Figure 5-4d), but both foal and adult BMSCs were only 10-20% lower (56% and 66%, 
respectively, p<0.001). In contrast, adult chondrocytes retained only 20% of the sGAG 
produced, nearly a factor of 4 less than the foal chondrocytes (p<0.001).  
The hydroxyproline content of the chondrocyte-seeded peptide hydrogels showed 
similar but less pronounced trends compared to sGAG content. Foal chondrocytes 
accumulated 10% and 50% higher hydroxyproline per gel than adult chondrocytes, 
without and with TGF-β1, respectively (Figure 5-4e, p<0.001). In contrast to sGAG, 
hydroxyproline content in adult chondrocyte hydrogels did not increase with TGF-β1 
stimulation. Also in contrast to sGAG, BMSC-seeded peptide hydrogels had higher 
hydroxyproline content than chondrocyte-seeded hydrogels. Without TGF-β1, both foal 
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and adult BMSC cultures had 30-40% higher hydroxyproline content per gel than either 
foal or adult chondrocytes (p<0.001). With TGF-β1 supplementation, hydroxyproline 
content of BMSC cultures was approximately a factor of 2 higher than foal and a factor 
of 3 higher than adult chondrocytes (p<0.001). These effects were even larger when 
normalized by wet weight, with BMSC cultures ~3-fold higher than foal and ~5-fold 
higher than adult chondrocytes with TGF-β1 stimulation (Figure 5-4f, p<0.001). 
Protein synthesis rates per cell during the final day of culture (measured by 3H-
proline incorporation, Figure 5-4g) were largely consistent with total hydroxyproline 
content. TGF-β1 stimulation produced 2- and 3-fold higher protein synthesis for foal and 
adult BMSC-seeded cultures than for chondrocyte-seeded peptide hydrogels, respectively 
(p<0.01) with statistically comparable protein synthesis for foal and adult cultures of both 
cell types. In TGF-β1-free cultures the only significant difference was a lower synthesis 
rate in adult BMSC hydrogels by a factor of ~4 vs. the other cell types (p<0.001). 
The ratio of dry weight to wet weight (percentage solid content) was higher for 
BMSC- than for chondrocyte-seeded peptide hydrogels, indicating greater total matrix 
density Figure 5-4h). In TGF-β1-free cultures, there was no significant difference 
between foal and adult chondrocytes (at approximately 1% solid), while foal and adult 
BMSCs were 20% and 80% higher, respectively (1.2% and 1.8%, p<0.05). Foal 
chondrocytes produced hydrogels that were nearly 2% solid with TGF-β1 stimulation, 
~2-fold higher than adult chondrocytes (p<0.001). BMSCs were 2-3 fold higher still 
(p<0.001), at 4% and 6% solid for foal and adult BMSCs, respectively. This greater 
matrix density observed for BMSC than for chondrocyte cultures in the presence of TGF-
β1 resulted from both higher dry weight due to matrix accumulation as well as lower wet 
weight due to BMSC-mediated hydrogel compaction. 
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Figure 5-4: Hydrogel ECM content and biosynthesis rates at day 21. sGAG content (a) 
per hydrogel (b) per wet weight. (c) Proteoglycan biosynthesis. (d) %sGAG retention. 
Hydroxyproline content (e) per hydrogel (f) per wet weight. (g) Protein biosynthesis (h) 
%Solid matrix. Stats: mean±sem, n = 2 foals × 4 samples each or n = 3 adults × 4 
samples each; * vs. Cntl; ‡ vs. foal chondrocyte; † vs. adult chondrocyte; p<0.05. 
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5.3.5.  Proteoglycan Size-Exclusion Superose 6 Chromatography 
The majority of proteoglycans synthesized in all samples eluted as an aggrecan-like peak 
[79] similar to proteoglycans extracted from young bovine cartilage tissue (Figure 5-5). 
Both foal BMSCs and chondrocytes also produced a low, broad peak, to the right of the 
aggrecan peak, that returned to baseline levels by Kav =0.3, suggesting a population of 
smaller proteoglycans was present in these samples [79]. All proteoglycans produced by 
adult BMSCs and chondrocytes eluted with a Kav less than 0.2, suggesting that these 
samples contained fewer small proteoglycans than the foal cells and were more similar to 
the native cartilage tissue extract. 
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Figure 5-5: Superose 6, size-Exclusion, proteoglycan chromatography. Proteoglycans 
extracted from either chondrocyte and BMSC seeded peptide hydrogels after 21 days of 
culture with TGF-β1 or from native cartilage tissue harvested from newborn bovine 
calves. 
5.3.6.  Aggrecan Monomer Ultrastructure via AFM Single 
Molecule Imaging 
Purified proteoglycan extracts from BMSCs and chondrocytes of both animal ages 
showed individual molecules that displayed a central core and numerous side chains 
(Figure 5-6), consistent with the known core protein-sGAG brush structure of aggrecan 
as previously visualized by AFM [91]. In some cases globular domains were visible on 
both ends of the core protein, consistent with full-length aggrecan having both G1- and 
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G3-globular domains, while in other cases the sGAG chains may have obscured the G3-
domain. Quantitative image analysis revealed that BMSCs from both foals and adults 
produced aggrecan with significantly longer average core protein length than 
chondrocytes, 487-503 nm vs. 412-437 nm, respectively (Figure 5-7a, p<0.05). Further 
analysis of the distribution of core protein length for all cell types (Figure 5-7b) revealed 
a peak between 500-600 nm, likely representing full-length aggrecan, and a tail that 
extended below 200 nm, likely due to catabolic processing of the aggrecan core protein. 
The aggrecan core protein distributions in Fig. 7B showed longer core protein for BMSC 
samples (26%-29% of aggrecan was >600 nm) than for chondrocyte samples (only 4%-
10% of aggrecan is >600 nm). Furthermore, 59%-60% of aggrecan core protein was <500 
nm in length for chondrocytes compared with only 31%-36% for BMSCs from either age 
donor, suggesting a potential increase in aggrecan cleavage in chondrocyte-seeded 
hydrogels. 
High magnification images of single aggrecan monomers had sufficient resolution to 
clearly distinguish and enable measurement of the lengths of individual CS-GAG chains 
as previously described [91]. CS-GAG chains on BMSC produced aggrecan were longer 
than on chondrocyte produced aggrecan for both foal cells (Figure 5-6e,f vs. Figure 5-
6b,c) and adult cells (Figure 5-6k,l vs. h,i). Image quantification confirmed this trend 
with BMSCs from both foals and adults producing 63-73 nm CS-GAG chains while 
chondrocytes produced CS-GAG chains between 40-46 nm (Figure 5-8a, p<0.05). To 
further quantify CS-GAG chain variability within a single aggrecan monomer, the 
distributions of CS-GAG chain lengths on a single monomer were measured. The 
examples shown in Figure 5-8b represent single monomers each displaying an average 
CS-GAG length near the population average of Figure 5-8a. The distributions for BMSC-
produced CS-GAG from both animal ages had higher standard deviation (11-14 nm) than 
for chondrocyte produced CS-GAG (7-8nm). 
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Figure 5-6: AFM Single-Molecule Height Images of Aggrecan Ultrastructure. 
Proteoglycans extracted from cell-seeded peptide hydrogels after 21 days of culture with 
TGF-β1. (a-c) Foal chondrocytes, (d-f) Foal BMSCs, (g-i) Adult chondrocytes, (j-l) Adult 
BMSCs. Blue arrows in a,d,g,j denote ends of full-length aggrecan monomers. 
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Figure 5-7: Aggrecan Core Protein Quantification. Aggrecan extracted from chondrocyte 
(Chd) and BMSC seeded peptide hydrogels after 21 days of culture with TGF-β1. (a) 
Core-protein average length. Stats: mean ± sem; n=110-231 aggrecan molecules; ‡ vs. 
foal chondrocyte; † vs. adult chondrocyte; p<0.05. (b) Histograms of core-protein length. 
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Figure 5-8: Aggrecan CS-GAG Chain Quantification. Aggrecan extracted from 
chondrocyte (Chd) and BMSC seeded peptide hydrogels after 21 days of culture with 
TGF-β1. (a) Average CS-GAG length per molecule. Stats: mean ± sem; n=28-35 
aggrecan molecules; ‡ vs. foal chondrocyte; † vs. adult chondrocyte; p<0.05. (b) 
Histograms of CS-GAG distribution on the single pictured molecule. Scale bar = 100 n 
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5.4 Discussion 
In this study we compared the cartilage-like neo-tissue formed by animal-matched equine 
BMSCs and chondrocytes as a function of animal donor age. Cells were encapsulated in a 
self-assembling peptide hydrogel and both tissue-level measurements to characterize 
matrix production and mechanical function and single-molecule measurements of ECM 
extracted aggrecan were made. Chondrogenesis was found to depend on the age of the 
equine tissue donor from which the cells were derived. For a skeletally-mature adult 
tissue source, BMSCs produced more sGAG and collagen and assembled a mechanically 
functional ECM with higher dynamic stiffness than that of primary chondrocytes. In 
addition, adult BMSCs proliferated during 3D peptide hydrogel culture in response to 
TGF-β1 stimulation, while adult primary chondrocytes did not. In contrast, BMSCs and 
chondrocytes from young tissue were both capable of proliferating and producing a 
mechanically functional tissue in 3D peptide hydrogel culture in the presence of TGF-β1. 
In the absence of TGF-β1, young primary chondrocytes demonstrated sGAG 
accumulation and proteoglycan synthesis that was greater than any other cell type in this 
study yet did not generate a tissue with more than an incremental increase in mechanical 
properties over cell-free controls. Given both the increases in DNA content per gel disk 
and the elevated DNA-normalized proteoglycan and protein biosynthesis rates with TGF-
β1 supplementation, the higher sGAG and hydroxyproline content of TGF-β1 stimulated 
neo-tissue was likely due to a combination of both cell proliferation and increased 
biosynthesis per cell. 
The conclusion that young BMSCs are capable of producing a comparable cartilage-
like ECM to young chondrocytes is in contrast to several recent reports using agarose gel 
culture, including studies [65,76,94] which showed inferior tissue forming capacity for 
BMSCs. However, these conclusions were predominantly based on culture in agarose 
hydrogels, whereas the present study utilized a self-assembling peptide hydrogel, which 
is known to enhance chondrogenesis of BMSCs relative to agarose [81]. When peptide 
hydrogels were used [76], close agreement with our results was reported at corresponding 
times in culture for both neo-tissue ECM content and dynamic mechanical stiffness. 
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Young equine chondrocytes proliferated in response to TGF-β1, whereas adult 
equine chondrocytes did not (Figure 5-3). Peptide gels seeded with young chondrocytes 
had higher sGAG accumulation and proteoglycan synthesis than adult chondrocytes both 
with and without TGF-β1 stimulation (Figure 5-4a and c). This is consistent with a recent 
report of decreased cellular proliferation and sGAG accumulation by human 
chondrocytes with age in pellet culture with TGF-β1 stimulation [70]. In addition, when  
bovine chondrocytes from fetal, young, and aged donors encapsulated in agarose, a 
decrease in cell proliferation and sGAG per cell was observed with age [72]. However, a 
significant decrease in hydroxyproline content and protein synthesis per cell with age was 
also reported [72], which was not consistent with the present study using peptide 
hydrogels. 
The dynamic stiffness of BMSC-seeded hydrogels from both young and adult 
sources was higher than for young chondrocytes (Figure 5-2), despite the higher total 
sGAG content for young chondrocyte-seeded hydrogels (Figure 5-4a). To interpret this 
result, we note that the observed frequency dependence of the dynamic stiffness is 
consistent with the known poroelastic behavior that characterizes transient and cyclic 
deformation in a variety of cell-seeded hydrogels [95-97], including the peptide 
hydrogels used here [98]. The simplest poroelastic description shows that gel dynamic 
stiffness is regulated by two intrinsic ECM material properties, the equilibrium modulus 
and hydraulic permeability, which are related to ECM composition [60,95,97]. While the 
equilibrium modulus and hydraulic permeability are both dependent on the sGAG content 
of the neo-tissue, they also depend on the density of the solid matrix [99]. Both young 
and adult BMSCs produced a much denser solid matrix (with TGF-β1, Figure 5-4h) with 
significantly higher collagen concentration (OH-Proline per wet weight, Figure 5-4f) and 
comparable sGAG concentration (sGAG per wet weight, Figure 5-4b) compared to young 
chondrocytes. In addition, BMSCs, but not chondrocytes, from both age donors 
compacted the hydrogel cultures further increasing the matrix density. Taken together, 
the BMSC-seeded hydrogels would be expected to have a lower hydraulic permeability 
than that of young chondrocytes [100,101], consistent with a higher dynamic stiffness. In 
addition, the CS-GAG chain length in both BMSC gels was significantly longer than that 
on aggrecan from primary chondrocytes, independent of age (Figure 5-7b). The presence 
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of longer CS-GAG chains is known to increase the nanomolecular compressive stiffness 
of aggrecan, as previously measured via AFM [5], which may result in increased stiffness 
of the macroscale construct (Figure 5-2). 
Size exclusion chromatography of the proteoglycans extracted from developing 
ECM of BMSC- and chondrocyte-seeded peptide hydrogels revealed that the 
predominant peak detected ran in the void volume of a Superose 6 column (Figure 5-5), 
consistent with the size of aggrecan [79]. This aggrecan peak was observed from ECM 
extracts from both young and adult cells. However, for both young BMSCs and 
chondrocytes an additional minor population of proteoglycans was observed near Kav = 
0.2 consistent with the size of decorin [79], whereas adult BMSCs and chondrocyte 
samples did not appear to contain a population of small proteoglycans. Alternatively, this 
population of smaller PGs could be comprised of enzymatically-cleaved aggrecan 
monomers; however, the resolution limitations of a Superose 6 column does not permit 
separating these various cleavage products, and hence more detailed analyses were 
performed via AFM imaging.  Nonetheless the chromatography detected predominantly 
full-length aggrecan, which was consistent with the histograms of core-protein length 
observed by AFM imaging (Figure 5-7b). 
When purified aggrecan extracted from BMSC- and chondrocyte-seeded hydrogels 
was imaged by tapping-mode AFM, the distribution of aggrecan core protein length for 
both young and adult donors was similar to reported results for aggrecan extracted from 
young native cartilage (Figure 5-7b; [28,31,35]). Ongoing studies have provided further 
evidence for the production of a young aggrecan phenotype by adult-BMSCs via 
fluorescence-assisted carbohydrate electrophoresis analysis of the CS-GAG chains [60]. 
These findings of consistent aggrecan ultrastructure as a function of BMSC- and 
chondrocyte-donor age was in contrast with the reported size variability seen for 
aggrecan extracted from native cartilage of different ages [28,31]. These differences are 
likely due to the diversity of aggrecan structures in adult articular cartilage, in which 
aggrecan half-life is known to be ~3.5 years [13], as compared to the newly synthesized 
aggrecan in the current study. Due to this long residence time in native adult cartilage, 
aggrecan is susceptible to sustained catabolic activity [102].  
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Nonetheless, aggrecan molecules with a range of shortened core protein lengths were 
observed in this study (Figure 5-7b), although differences in prevalence of this shortened 
aggrecan were mainly between chondrocytes and BMSCs and not related to age. One 
potential explanation for the differences in aggrecan core protein length is that TGF-β1 
stimulation has been shown to increase catabolic processing of aggrecan in chondrocyte-
seeded agarose [65]. In contrast, aggrecan catabolic activity by BMSCs in TGF-β1 
stimulated peptide hydrogels is limited [81]. Thus, the unique distributions of aggrecan 
core protein length for BMSCs and chondrocytes may be a result of catabolic processing 
and influenced greatly by the choice of scaffold, cell-scaffold interactions, and cell-type 
specific responses to TGF-β1 stimulation. 
Another unique feature of BMSC produced aggrecan was the trend for molecules to 
be substituted with elongated CS-GAG chains, which were 40%-75% longer than those 
on articular chondrocyte aggrecan (Figure 5-8). These elongated CS-GAG chains may 
indicate a distinct regulatory pathway for CS-GAG biosynthesis in the newly 
differentiated BMSC population. GAG production is now understood to be independently 
regulated by expression and organization of transporters and polymerizing enzymes 
[8,103]. CS-GAG elongation has been shown to be enhanced by PDGF, TGFb1, and 
thrombin [8]. This has been attributed to downstream signaling mechanisms that enhance 
transcription and translation of the CS-GAG synthesizing enzymes [104,105] and that 
may also affect spatial organization of these proteins into cell type specific 
GAGOSOMES [103]. This suggests that BMSC- and chondrocyte-specific responses to 
TGF-β1 stimulation may be responsible, in part, for the observed differences in CS-GAG 
length. One consequence of these elongated CS-GAG chains on BMSC produced 
aggrecan is that their high anionic charge density and close packing on the core protein 
would lead to a higher GAG-GAG repulsive force which can extend the core protein 
length of individual monomers [91]. Consistent with this phenomenon, the histograms in 
Figure 5-7b were shifted towards longer core protein length for BMSC-produced 
aggrecan. 
Adult BMSCs encapsulated in a self-assembling peptide hydrogel with TGF-β1 
stimulation demonstrated robust cartilage ECM production that was dramatically superior 
to animal-matched adult chondrocytes, whereas similarly cultured foal chondrocytes had 
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comparable ECM production to foal BMSCs. The newly secreted ECM was mechanically 
functional and the matrix biochemical composition was consistent with a poroelastic 
molecular mechanism for the measured mechanical moduli. Detailed AFM analysis of 
aggrecan monomers synthesized by BMSCs and chondrocytes revealed longer core-
protein length and CS-GAG chain length for BMSCs than for chondrocytes, consistent 
with a younger phenotype for BMSC-produced neo-tissue [31,35,71]. Taken together, 
these differences suggest potential advantages for BMSCs over chondrocytes for use in 
cell-seeded cartilage repair strategies, especially when it is desirable to use autologous 
cells for treatment of adult patients. Future work on BMSC based therapies will need to 
develop techniques for maintaining the chondrogenic phenotype established during the 
early chondrogenesis described in this study, without inducing hypertrophy and terminal 
differentiation. These techniques could potentially involve modifying the cell culture 
scaffold with bioactive motifs to control the BMSC differentiation state throughout the 
course of neo-tissue formation, integration with surrounding native tissue, and return to 
full mechanical and physiologic function.  
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Chapter 6  
Adult Bone Marrow Stromal Cell- 
based Tissue-engineered Aggrecan 
Exhibits Ultrastructure and 
Nanomechanical Properties Superior 
to Native Cartilage 
This chapter was submitted as a paper to Osteoarthritis and Cartilage in 2010. 
Authors: Hsu-Yi Lee, Paul Kopesky, Anna Plaas, John Sandy, John Kisiday, David 
Frisbie, Alan Grodzinsky, and Christine Ortiz 
6.1 Introduction 
Tissue engineering substitutes have great potential for the restoration of the biological 
function of damaged and diseased cartilage [106], which has limited intrinsic self-
regeneration capabilities. Approaches to cartilage tissue engineering involve numerous 
design considerations involving cell source (e.g. chondrocytes, synoviocytes, 
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marrow/adipose-derived progenitor cells), biocompatible scaffold chemistry and 
morphology, bioactive signaling factors that promote cellular differentiation, maturation, 
and extracellular matrix synthesis, mechanical stimulation, gene therapy, 
microenvironmental factors and bioreactors [107]. While many tissue engineering 
methodologies produce cartilage-like neo-tissues with similar macromolecular 
components compared to the native cartilage extracellular matrix (ECM), a major 
challenge is to produce constructs having biochemical, structural and biomechanical 
properties that are functionally equivalent to cartilage in vivo [108]. 
The overall composition and organization of neocartilage is typically characterized 
via biochemical [89,109], histological and immunohistochemical [110] measures, while 
ECM molecular constituents have been analyzed using various chromatographic [111] 
and electrophoretic techniques [112,113]. Tissue-level biomechanical measurements to 
quantify the compressive, tensile and shear behavior [17,114] of neocartilage are related 
to and ultimately determined by the macromolecular constituents and assembly of the 
ECM [115,116]. Recently, high resolution imaging and nanomechanical methodologies 
have been developed to directly visualize the detailed intramolecular structure and probe 
the nanoscale mechanical properties of various ECM constituents (e.g., aggrecan [4,5], 
collagen [117,118], hyaluronan [57]). These techniques provide an understanding of 
molecule-to-molecule variability, intramolecular and local nanoscale properties, and the 
ability to assess properties of selected sub-populations that cannot be revealed by 
macroscopic measures which provide population averages. The combination of new 
nanotechnological approaches with traditional biochemical, histological, and 
macroscopic mechanical methods, can greatly assist in understanding, evaluating and 
optimizing a proposed tissue engineered strategy.  
Because aggrecan is the dominant compressive load-bearing macromolecule in 
cartilage ECM [13], its expression, synthesis, organization, and turnover are often used as 
biomarkers of the chondrogenic potential of bone marrow stromal cells (BMSCs) in cell-
based cartilage tissue engineering [65-67]. Recent studies showed that the sulfated 
glycosaminoglycan (sGAG) content of BMSC-seeded agarose and self-assembling 
peptide hydrogels was lower than that in parallel hydrogels seeded with chondrocytes 
from skeletally-immature cartilage [60,66], and varied with scaffold material [60,76]. 
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Aggrecan accumulated within BMSC-seeded constructs was structurally different from 
that in native cartilage or in similar hydrogels seeded with chondrocytes. In agarose, 
BMSC-synthesized aggrecan was shown by Western analysis to be primarily full-length 
[65]; in the peptide gel, atomic force microscopy (AFM) imaging showed that BMSC- 
aggrecan had longer core protein and larger GAG chain length [60]. The chondrogenic 
potential of adult human BMSCs was found to be independent of age or osteoarthritis 
(OA) [16], an advantage of using BMSCs over chondrocytes for autologous cell-based 
cartilage repair [75] for older OA patients, where the source and capacity of chondrocytes 
are limited. Given these advantages of BMSC-based cartilage repair, rigorous molecular-
level characterization of BMSC-produced ECM is needed to further understand adult 
BMSC chondrogenesis. 
The goal of this study was to investigate aggrecan produced by adult equine BMSCs 
encapsulated in peptide hydrogels and induced to undergo chondrogenic differentiation 
and to compare with aggrecan extracted from age-matched adult equine articular cartilage. 
The detailed molecular structure and properties of aggrecan were quantitatively assessed 
using high resolution AFM-based approaches.  First, the ultrastructure of these two 
aggrecan populations was investigated via AFM-based single molecule imaging. 
Secondly, the aggrecan-GAG sulfation patterns and extent of core protein proteolysis was 
characterized using fluorescence-assisted carbohydrate electrophoresis (FACE) [112] , 
Western blot, and size-exclusion chromatography analyses. Finally the nanomechanical 
properties of these two aggrecan populations were evaluated using high resolution force 
microscopy. Adult BMSC-peptide aggrecan demonstrated ultrastructural features and 
GAG sulfation similar to those of skeletally-immature (young) cartilage aggrecan, and 
had increased compressive stiffness compared to adult cartilage aggrecan.  
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6.2 Methods 
6.2.1.  Tissue Harvest 
Cartilage tissue was harvested aseptically from the femoropatellar groove, and bone 
marrow was harvested from three skeletally-mature (2-5 year-old adults) mixed-breed 
horses as described previously [60]. Horses were euthanized at Colorado State University 
for reasons unrelated to this study, and for conditions that would not affect either 
cartilage or bone marrow. 
6.2.2.  Marrow Stromal Cell Isolation 
BMSCs were isolated and stored as previously described [60]. Marrow samples were 
washed in PBS and fractionated by centrifugation to separate the nucleated cells from the 
red blood cells. BMSCs were isolated by differential adhesion to tissue culture plastic. 
After BMSC colonies reached local confluence, cells were detached and reseeded at 
6×103 cells/cm2, expanded to ~3×104 cells/cm2 over three days, and cryo-preserved. 
Before hydrogel encapsulation, BMSCs were thawed and plated at 6×103 cells/cm2. After 
3 days, cells were detached (passage-1) and reseeded at 6×103 cells/cm2, and expanded 
for three days prior to encapsulation in peptide hydrogels. 
6.2.3.  Hydrogel Encapsulation and Culture 
KLD12 peptide with the sequence AcN-(KLDL)3-CNH2 was synthesized by the MIT 
Biopolymers Laboratory (Cambridge, MA) using an ABI Model 433A peptide 
synthesizer with FMOC protection. BMSCs were encapsulated in 0.35% (w/v) KLD12 
peptide at a concentration of 10×106 cells/ml using acellular agarose casting molds to 
initiate peptide assembly as described previously [60]. BMSC-seeded disks (6.35mm-
diam×1.6mm-thick) were cultured in high glucose DMEM (Invitrogen, Carlsbad, CA) 
supplemented with 1% ITS+1 (final concentration: 10 μg/ml insulin, 5.5 μg/ml transferrin, 
5 ng/ml sodium selenite, 0.5 mg/ml bovine serum albumin, 4.7 μg/ml linoleic acid, 
Sigma-Aldrich), 0.1 μM dexamethasone (Sigma-Aldrich, St. Louis, MO), 37.5 μg/ml 
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ascorbate-2-phosphate (Wako Chemicals, Richmond, VA), 1% PSA, 10 mM HEPES, 
400 μM L-proline, 1mM sodium pyruvate, and 1% NEAA, with 10 ng/ml rhTGF-β1 
(R&D Systems, Minneapolis, MN) with medium changes every 2-3 days. Disks were 
cultured for 21 days. 
6.2.4.  Aggrecan Extraction 
Aggrecan was extracted from BMSC-peptide gels and native articular cartilage (Figure 6-
1a) with 4M guanidine HCl, 100 mM sodium acetate, pH 6.8, containing Protease 
Complete inhibitor mix (Roche, Indianapolis, IN) for 48 hours at 4ºC with agitation [35]. 
Extracts were adjusted to 1.58g/ml by the addition of CsCl and centrifugation at 470,000 
gav for 72 hours at 4ºC. The D1 fractions (>1.54 g/ml) were desalted by dialysis against 
water, dried and used for AFM imaging, nanomechanical testing, and Western analysis. 
Unfractionated GuHCl extracts were also desalted and used for FACE analysis [112]. 
6.2.5.  AFM Imaging 
D1 aggrecan samples at 50 μg sGAG/ml in MilliQ water were deposited on 3-
aminopropyltriethoxysilane (APTES; Sigma Aldrich, St. Louis, MO) functionalized 
muscovite mica substrates (SPI Supplies, West Chester, PA) and rinsed with MilliQ 
water after 30 minutes, as previously described [4]. Electrostatic interactions between the 
positively charged APTES-mica and the negatively charged GAG chains retained 
aggrecan on the surface in a relatively flat conformation [4], despite rinsing in water. 
Tapping mode imaging (Figure 6-1b) was performed in ambient conditions with a 
Nanoscope IIIa Multimode AFM (Veeco Instruments, Plainview, NY) and Super Sharp 
Silicon AFM probes (nominal cantilever spring constant = 42N/m, nominal tip end radius 
<5 nm; Nanosensors, Switzerland). A thin layer (0.2-1 nm) of absorbed water is present 
on mica under ambient conditions [92] which partially hydrates the aggrecan.  
6.2.6.  Quantification of Aggrecan Single Molecule Dimensions 
AFM height images were digitized into pixels and aggrecan structural features (ie. core 
protein and GAG trace length) were traced and calculated automatically with a custom 
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Matlab program (The MathWorks, Natick, MA) or manually with SigmaScan Pro image 
analysis software (SPSS Science, Chicago, IL). Full-length aggrecan were identified 
quantitatively by the presence of G1 and G3 domains having increased height (>0.5 nm) 
at the ends of the core protein.  
 
Figure 6-1: (a) Aggrecan was extracted from adult equine BMSC-peptide gels (after 21 
days of culture) and from adult equine articular cartilage. The model of full-length 
aggrecan shows the globular domain structures labelled as G1,G2,G3, linked by a core 
protein substituted with keratan sulfate (KS) and, chondroitin sulfate (CS). (b) An 
illustration of aggrecan imaging using AFM tapping mode. Aggrecan molecules were 
immobilized on the APTES-modified mica substrate in a flattened conformation and 
imaged by a sharp silicon probe tip. (c) Illustrations of AFM nanomechanical testing. 
Micro-contact-printed aggrecan patterns were surrounded by self-assembled monolayer 
molecules (11-mercaptoundecanol, HS(CH2)11OH, OH-SAM). A spherical gold-coated 
glass tip (functionalized with of OH-SAM) was used to scan and compress the aggrecan 
patterns. The experiment was performed in 0.001-1.0M NaCl (pH ~ 5.6). (d) Height-
normal force measurement: contact mode imaging was used to apply a range of normal 
compressive forces while scanning across the patterned surface to measure the 
compressed height H of aggrecan. (e) Normal force-distance measurements: direct 
compression of aggrecan was performed by having the probe tip approach the surface 
perpendicular to the plane of the substrate and measuring the force as a function of tip-to-
substrate distance D.  
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6.2.7.  Aggrecan Nanomechanical Testing 
Microcontact printing [119] was employed to produce micrometer-sized hexagonally-
patterned surfaces of densely packed, chemically end-grafted aggrecan surrounded by a 
neutral hydroxyl-terminated self-assembled monolayer (11-mercaptoundecanol, 
HS(CH2)11OH, OH-SAM) [5] (Figure 6-1c). A Multimode picoforce Nanoscope IV AFM 
(Veeco Instruments, Plainview, NY) was used to perform compressive nanomechanical 
testing with an OH-functionalized spherical colloidal probe tip [5] (cantilever spring 
constant ~0.12 N/m, tip end radius ~2.5 µm; Novascan, Ames, IA). Two measurements 
were employed to assess the mechanical stiffness of the aggrecan. First, the absolute 
compressed height H of aggrecan as a function of applied normal force was obtained by 
scanning parallel to the substrate surface and across the hexagon region [5] (Figure 6-1d) 
using contact mode imaging over a wide range of normal forces (0~30 nN), and in 
aqueous solutions of 0.001 to 1M NaCl (pH ~5.6). Secondly, normal compression of 
aggrecan was performed by having the probe tip approach perpendicularly to the 
substrate (z-piezo displacement velocity = 2 µm/s, Figure 6-1e). Raw data were 
converted to normal force as a function of tip-to-substrate distance, D as described 
previously [5]. Do is defined as the D where the force first increases above noise level. 
Normal stress was calculated from the normal force using the surface element integration 
method [5,120]. The total sGAG content within a hexagon on the gold substrate was 
measured by dimethylmethylene blue dye assay (DMMB) [89] after testing. The initial 
sGAG density prior to compression, calculated by dividing the sGAG content by pattern 
volume, was ~20 mg/ml (one aggrecan molecule per ~25 nm × 25 nm) at 0.1M NaCl for 
both BMSC-peptide and cartilage-extracted aggrecan samples. sGAG density during 
compression was calculated as a function of compressed height by normalizing the total 
sGAG content under the probe tip to the reduced compressed volume. (This estimate of 
density assumes minimal outward “bulging” of aggrecan at the radial periphery of the 
layer under the tip. Since the tip diameter (2R)>>Do and, given the lateral constraint of 
the adjacent uncompressed aggrecan, this assumption is reasonably well justified.)  
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6.2.8.  Core Protein Heterogeneity  
Aggrecan core protein heterogeneity was analyzed by Western blotting. Samples were 
treated with protease-free chondroitinase ABC (30mU/100μg GAG), keratanase II 
(0.5mU/100μg GAG) and endo-β-galactosidase (0.5mU/100μg GAG) (Seikagaku, Tokyo, 
Japan) and digests corresponding to 10µg GAG were loaded on 4-15% polyacrylamide 
gels and probed with antibodies to the aggrecan G1 (JSCATEG) [80].  
6.2.9.  Aggrecan and GAG Hydrodynamic Size 
Sephacryl S-1000 and Superose 6 FPLC chromatography (GE Healthcare, Piscataway, 
NJ) were used to characterize the hydrodynamic size distributions of aggrecan monomers 
and their constituent GAG chains, respectively. Aggrecan (200 µg sGAG) was eluted on 
S-1000 at 30 ml/hr with 0.5M sodium acetate at pH 6.8. For GAG analysis, 100µg 
aggrecan was digested with 50 µg proteinase K in 200 µl ammonium acetate (pH 7.2) for 
48 hrs at 60 °C and 100 µl of the digest was eluted on Superose 6. Fractions (0.5 ml) 
were collected at 0.5 ml/min and assayed for sGAG by DMMB. The void volume Vo and 
total volume Vt were determined using 0.5 µm polystyrene beads and phenol red, 
respectively. The partition coefficient (Kav) was estimated as (Ve -Vo)/(Vt -Vo), for each 
eluted fraction Ve. 
6.2.10.  FACE Analysis of GAG Sulfation 
FACE analysis was performed on proteinase K digests of BMSC-peptide aggrecan from 
3 different adult horses and cartilage-extracted aggrecan from 1 adult horse. Samples 
containing 2-10 µg of sGAG were digested with chondroitinase ABC, disaccharide 
products fluorotagged by reductive amination with 2-aminoacrodone, prior to separation 
and quantitation by FACE [112].  
6.2.11.  Statistical Analyses 
Aggrecan and GAG molecular dimensions are reported as mean ± SD in text and in 
figures for population distribution. For data-sets having a unimodal distribution, a 
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Gaussian fit was used to test for normality, and the goodness of fit was evaluated by R2 
(the summed mean squares of the regression divided by the summed mean squares of the 
data). For normally distributed data-sets, two-tailed, unpaired Student t-tests were 
performed to test for differences of the means, with significance set at p<0.05. For non-
unimodal distributions, a two-sample Kolmogorov-Smirnov (K-S) test was performed to 
compare distributions of molecular dimensions. For comparison between groups, 95% 
confidence intervals were used. 
6.3 Results 
6.3.1.  Single molecule ultrastructure of BMSC-peptide and 
native cartilage aggrecan 
AFM height images compare the ultrastructure of BMSC-peptide aggrecan (Figure 6-2a-c) 
to cartilage-extracted aggrecan (Figure 6-2d-f). Individual aggrecan molecules were 
directly visualized and the details of their intramolecular structure including the core 
protein and constituent GAG chains identified (Figure 6-2b,c,e,f). In many cases, the 
brighter globular domains (G1, G3) at the ends of the core protein (arrows in Figure 6-
2a,d) could be identified by their increased height (>0.5 nm) relative to the rest of the 
molecule. Aggrecan with globular domains at both N (G1)- and C (G3) termini were 
identified as "full-length," i.e., those which had not been enzymatically cleaved along the 
core protein [9,121]. The molecular dimensions of the aggrecan from the two sources 
were strikingly different. The BMSC-peptide aggrecan had noticeably longer GAG 
chains than cartilage-extracted aggrecan (Figure 6-2b,c vs. Figure 6-2e,f, quantified 
below). Moreover, short fragments (Figure 6-2d, asterisks) were more pronounced in the 
cartilage-extracted aggrecan population than in BMSC-peptide aggrecan (quantified 
below). 
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Figure 6-2: AFM height images of aggrecan monomers. (a)-(c) Aggrecan produced by 
adult equine BMSCs seeded in peptide hydrogel. (d)-(f) Aggrecan extracted from adult 
equine articular cartilage. In (a) and (d), the globular domains of full length aggrecan are 
indicated by arrows. Example of short degraded aggrecan fragments (~100 nm) are 
marked by asterisks in (d). Examples of core protein and GAG chain traces are shown in 
(b). 
6.3.2.  Core protein length distribution and heterogeneity 
The distributions of the core protein trace length for the BMSC-peptide and cartilage-
extracted aggrecan were markedly different (K-S test, p<0.0001, Figure 6-3a,b), with 
BMSC-peptide aggrecan = 440 ± 138nm (mean±SD) and cartilage-extracted aggrecan = 
220 ± 142 nm. While the length distributions were broad and nearly bimodal (Figure 6-
3a,b), the constituent sub-populations of full-length aggrecan (Figure 6-2c,d) were both 
normally distributed with peaks at 487 nm and 475 nm that were not significantly 
different from each other (p = 0.32). A large proportion (~40%) of the BMSC-peptide 
aggrecan was full-length (Figure 6-3a,c), whereas the majority of the cartilage aggrecan 
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(~86%) were fragments (Fig. 3b,d) consistent with proteolytic degradation. Full-length 
cartilage-extracted aggrecan comprised a smaller sample size (n = 20, Figure 6-3d) due to 
the lower proportion of full-length aggrecan observed in the whole population. The 
difference in size of the molecular populations was also seen in the S-1000 
chromatograms (Figure 6-3e): BMSC-peptide aggrecan eluted earlier (Kav = 0.25) than 
the cartilage-extracted aggrecan (Kav = 0.42), consistent with the larger average 
hydrodynamic size of BMSC-peptide aggrecan.  
Western analyses were performed on the same samples to further assess the 
heterogeneity of the core protein constituents by using antibodies against the G1 domain 
of the core proteins. The BMSC-peptide aggrecan showed a greater abundance of high-
molecular-weight species reacting with anti-G1 antibody, consistent with a larger 
population of full-length aggrecan (Figure 6-3f). The major G1-immunoreactive fragment 
seen in both the BMSC-peptide and cartilage-extracted aggrecan samples was similar to 
the molecular weight of a previously characterized calpain-generated "double-globe" 
species (~120kDa) [121]. Based on a comparison with our recent study of BMSC-
aggrecan which used G1-NITEGE anti-neoepitope analysis [81], the G1-containing bands 
between 56-101kDa are likely the G1-NITEGE products associated with aggrecanase-
mediated cleavage [9]. 
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Figure 6-3: Core protein analyses. Core protein trace length distributions of (a) BMSC-
peptide aggrecan and (b) cartilage-extracted aggrecan measured from the AFM height 
images. (Mean ± SD is noted in each histogram. n = number of measured aggrecan 
molecules.) The distributions of the two core protein populations (a,b) are markedly 
different (K-S test, p<0.0001). Core protein trace length distributions of full-length (c) 
BMSC-peptide aggrecan and (d) cartilage-extracted aggrecan. Gaussian curves were fit to 
both distributions; the goodness of fit R2 is 0.997 and 0.974 in (c) and (d), respectively. 
These two core protein length distributions (c,d) are not significantly different (two-tailed 
t test, p = 0.3531.) (e) Elution profiles of BMSC-peptide and cartilage-extracted aggrecan 
on a Sephacryl S-1000 column. Kav = 0.25 for the BMSC-peptide aggrecan and 0.42 for 
the cartilage-extracted aggrecan, indicating the greater hydrodynamic size of BMSC-
peptide aggrecan. (f) Western blot analysis with anti-G1 antibody. High molecular weight 
core protein as well as low molecular weight core fragment species (*) were detected in 
both BMSC-peptide and cartilage-extracted aggrecan samples. 
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6.3.3.  GAG Chain Length and Sulfation 
The distribution of individual GAG chain lengths within a single representative full-
length aggrecan in the BMSC and cartilage populations of Figure 6-3c,d is shown in 
Figure 6-4a,b, respectively. The selected full-length BMSC-peptide aggrecan has longer 
average GAG length (47 ± 8 nm, n = 41 chains, Figure 6-3e) than that of the single 
cartilage-aggrecan (17 ± 7 nm, n = 44 chains, Figure 6-3f). The GAG chains of this 
BMSC-peptide aggrecan also have a broader length distribution than that of the cartilage-
extracted aggrecan (Figure 6-4a,b). For multiple aggrecan molecules, GAG chain lengths 
were measured and an average chain length per molecule was calculated (Figure 6-4c,d). 
The mean of the average GAG length per molecule was 44±10nm for BMSC-aggrecan (n 
= 299, Figure 6-4c) and 20 ± 4 nm for cartilage-aggrecan (n = 87, Figure 6-4d). The n 
(number of measured aggrecan molecules) in Figure 6-4d was smaller than that in Figure 
6-3b because some fragments did not have detectable GAG chains. For the full-length 
aggrecan populations of Figure 6-3c,d, the corresponding GAG trace length of BMSC-
peptide aggrecan was about twice as long as that of cartilage-aggrecan (Figure 6-4e,f). 
For both “all observed” (Figure 6-4c,d) and “full-length” (Figure 6-4e,f) aggrecan 
populations, the mean GAG chain length per aggrecan molecule of the BMSC-peptide 
aggrecan was significantly longer than that of cartilage-extracted aggrecan (p<0.0001). 
For each population (BMSC-peptide or cartilage-extract), the “all observed” and “full-
length” aggrecans had similar GAG lengths (p = 0.175 and 0.642, respectively).  
The average hydrodynamic size of BMSC- and cartilage-aggrecan GAG chains was 
also assessed by Superose 6 size-exclusion chromatography (Figure 6-3g). The BMSC-
aggrecan GAGs eluted at Kav = 0.50 while cartilage-extracted GAGs eluted at Kav = 0.71, 
corresponding to average chain lengths of ~60 disaccharides (27kDa, corresponding to 
~60 nm contour length) and ~30 disaccharides (13kDa, ~30 nm), respectively [122].  
FACE analyses showed that aggrecan CS chains produced by peptide-encapsulated 
BMSCs from 3 adult equines were composed of approximately equimolar amounts of 4- 
and 6-sulfated disaccharides, a ratio characteristic of skeletally-immature and growing 
cartilage. In contrast, the adult cartilage-extracted aggrecan showed a higher proportion 
of 6-sulfated disaccharides, typical of adult cartilage [123].  
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Figure 6-4: GAG chain length and composition analysis. Distribution of GAG trace 
lengths on one selected single representative (a) BMSC-peptide aggrecan and (b) 
cartilage-extracted full-length aggrecan. Mean ± SD is noted in each histogram. n = 
number of measured GAG chains. Distribution of average GAG chain lengths for 
multiple (c) BMSC-peptide aggrecan and (d) cartilage-extracted aggrecan. n = number of 
measured aggrecan molecules. Distribution of average GAG chain length on multiple 
full-length (e) BMSC-peptide aggrecan and (f) cartilage-extracted aggrecan. n = number 
of measured aggrecan molecules. The goodness of the Gaussian fit R2 in (c)-(f) is 0.971, 
0.968, 0.901 and 0.999, respectively. (g) Superose 6 chromatography shows the BMSC-
peptide GAG population is longer than the cartilage-extracted GAG population with Kav 
=0.50 and 0.71, respectively. (h) FACE analysis of aggrecan produced by BMSCs 
derived from 3 adult horses and that of aggrecan extracted from adult cartilage. The 
BMSC-peptide aggrecan showed an approximately equal amount of ΔDi6S and ΔDi4S in 
contract to the increased ΔDi6S content of cartilage-extracted aggrecan. 
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6.3.4.  Aggrecan Compressive Stiffness 
The three-dimensional AFM height images of microcontact printed substrates verified the 
presence of clear hexagonal patterns of both BMSC-peptide and cartilage-extracted 
aggrecan (Figure 6-5a,b). Consistent with previous results [5], the aggrecan height, H, 
decreased monotonically with increasing ionic strength and with increasing normal force 
during a lateral scan and reached the final incompressible height by ~30 nN force (Figure 
6-5c,d). The initial heights at low force reflect the relative differences in lengths of the 
two aggrecan populations observed via AFM imaging. At any given ionic strength, the 
BMSC-peptide aggrecan pattern showed ~2-3 fold longer initial height than cartilage-
aggrecan.  
In the one-dimensional force-distance measurements (Figure 6-5e,f), normal force 
increased markedly with compression (decreasing D) as observed previously with fetal 
bovine aggrecan [5]. At any given ionic strength, the BMSC-peptide aggrecan exerted a 
repulsive force against tip at longer Do (e.g., Do ~600 nm for BMSC-peptide aggrecan 
and ~200 nm for cartilage-aggrecan in 0.001M NaCl (Figure 6-5e,f)), reflecting the larger 
initial height and stronger electrostatic repulsion interactions of BMSC-peptide aggrecan. 
The compressive properties studied with these two different nanomechanical 
methodologies, height-force and force-distance, coincide well with each other (Figure 6-
5g). The small difference between H and D at low force (<5 nN) was likely due to the 
tare force (~100 pN) necessary to enable stable feedback during imaging [5]. 
Finally, to directly compare the compressive stiffness of the two aggrecan 
populations independent of their different initial heights (i.e., core protein lengths), the 
force-distance curves of Figure 6-5e,f were converted to stress versus DMMD-measured 
sGAG-concentration (see Methods). At physiological ionic strength (0.1M NaCl), the 
normal stress increased markedly with increasing compression (i.e., density of 
compressed GAG), but much more dramatically for the BMSC-peptide aggrecan (Figure 
6-6).  
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Figure 6-5: Nanomechanical testing. (a,b) AFM three-dimensional height images of (a) 
BMSC-peptide and (b) cartilage-extracted aggrecan chemically end-grafted on gold 
substrates and patterned by micro-contact printing. The images were taken in 0.001M 
NaCl with a minimal applied normal force ~100 pN. (c,d) Compressed aggrecan height H 
versus normal force curves of (c) BMSC-peptide and (d) cartilage-extracted aggrecan in 
different ionic strength aqueous solution were measured by contact mode AFM. Insert in 
(d) shows the direction of the scan and the corresponding compressed height H. Each 
data point represents the average aggrecan height from 8 scans across the pattern at a 
given normal force and NaCl concentration. The standard deviation (SD) of each data 
point is smaller than the size of the data point. (e,f) Normal force versus distance curves 
of (e) BMSC-peptide and (f) cartilage-extracted aggrecan during normal compression as 
shown in the insert in (f). The probe tip approaches the substrate perpendicular to the 
plane of the substrate. Each curve is an average of 30 approaches in different locations on 
the pattern. The SD of each averaged curve is smaller than the line width. (g) Comparison 
of the height-normal force measurement (open triangles, replotted from Figure 6-5c,d, 
0.01M NaCl) and normal force-distance measurements (lines, replotted from Figure 6-
5e,f, 0.01M NaCl). Data measured using two different methods well coincide. Some 
slight discrepancy at low normal force (< 5 nN) is possibly due to the finite normal force 
necessary for maintaining stable feedback during the contact mode scanning. 
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Figure 6-6: Stress-sGAG concentration curves converted from the force-distance curves 
in Figure 6-5e,f (0.1M NaCl). The initial uncompressed sGAG concentration was the 
total sGAG amount measured by DMMB divided by the aggrecan pattern volume 
measured by AFM height images. Normal stress was calculated from the force using the 
surface element integration method[120]. Upon compression by the probe tip, the sGAG 
density of the end-grafted aggrecan under the probe tip increased due to the decrease in 
compressed volume. When both aggrecan patterns were compressed to the same sGAG 
concentration, BMSC-peptide aggrecan exhibited greater stress than the cartilage-
extracted aggrecan. (note: GAG concentration in native tissue is 20-80 mg/ml)[3]. Each 
curve is an average of 30 approaches in different locations on the aggrecan pattern. The 
95% confidence intervals of each averaged curve are smaller than the line width. 
6.4 Discussion 
This study of aggrecan macromolecules from tissue-engineered constructs and native 
cartilage involved the combination of high resolution AFM-based techniques to quantify 
nanoscale structure and nanomechanical properties. Such an approach can provide a 
platform for optimization of cell source, scaffold and culture conditions. AFM imaging 
enabled visualization of single molecules and their inter- and intramolecular 
heterogeneity. Marked differences were observed between adult BMSC- and cartilage-
aggrecan populations. BMSC-aggrecan was predominantly full-length with fewer 
proteolytically degraded fragments and much longer CS-GAG chains than cartilage 
aggrecan. These detailed AFM-based measurements were consistent with size-exclusion 
chromatography and Western analyses. In addition, AFM nanomechanical measurements 
showed that the compressive stiffness of the BMSC-aggrecan was markedly higher than 
that of cartilage aggrecan. Taken together, these results suggest that adult BMSC-
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aggrecan exhibits characteristics more similar to those of skeletally-immature growth 
cartilage than to adult cartilage. 
Imaging of single molecules revealed that aggrecan synthesized by adult BMSCs in 
peptide hydrogel had an overall morphology qualitatively similar to that in adult cartilage, 
consisting of a GAG-functionalized core protein [13]. However, the two aggrecan 
populations had strikingly different molecular dimensions (Figure 6-2 and Figure 6-3). 
Based on AFM imaging, 50% of the BMSC-aggrecan had a core protein length >400 nm, 
compared to only 16% of the cartilage-aggrecan (Figure 6-3a,b). S-1000 chromatography 
demonstrated average molecular sizes that were consistent with AFM-based results. 
Western analyses suggested that the major G1-immunoreactive constituents of cartilage-
aggrecan were fragments which have been previously shown to be generated by 
aggrecanases [9] (G1-NITEGE) and m-calpain [121] (G1-G2-GVA). In contrast, BMSC-
peptide aggrecan was predominantly full-length, typical of aggrecan from immature 
cartilage [4,124]. The activity of aggrecan proteolytic enzymes is known to be regulated 
by TGF-β, but evidence exists for both inhibition [125] and upregulation [126] of 
proteolysis.   Interestingly, if compared to the aggrecan produced by adult articular 
chondrocytes under the identical conditions with TGF-β stimulation[60], the adult 
BMSC-aggrecan have a larger proportion of full-length core proteins than the adult 
chondrocyte-aggrecan. The full-length BMSC- and cartilage-aggrecan had similar core 
protein trace lengths exhibiting a Gaussian distribution (Figure 6-3c,d). Together, these 
results suggest that the decreased average core protein trace length seen in the entire 
cartilage-aggrecan population was due to proteolytic degradation. 
The GAG chains of BMSC-aggrecan were found to be more than two times longer 
than that of cartilage-aggrecan (Figure 6-4). CS chain length has been shown to decrease 
with age in cartilage tissue [35,127] and is also smaller when synthesized by adult 
chondrocytes cultured in vitro, reflecting an age dependent alteration of aggrecan-GAG 
synthesis [128]. Longer GAGs are prevalent in aggrecan from immature cartilage 
[21,127], growth plate [122] and newly synthesized aggrecan after injury [129], as well 
as during the early stages of osteoarthritis [130]. The latter two studies hypothesized that 
the increased CS chain length in injured and OA-cartilage were indicative of growth 
cartilage metabolic phenotype. The CS sulfation fine structure analyses are also 
 105
consistent with such a conclusion. The sulfation patterns of CS-GAGs analyzed by FACE 
have been studied previously as a characteristic of animal age, GAG chain termination, 
tissue differentiation and development [21,131,132]. Adult BMSCs synthesized CS with 
~1:1 ΔDi6S-to-ΔDi4S ratio, similar to that observed previously in skeletally-immature 
and growing cartilage [122,123], while adult cartilage contained aggrecan predominantly 
with 6S-sulfated CS (Figure 6-4), consistent with previous studies [123]. The differences 
in the GAG structure between the two aggrecan populations in this study suggest that 
adult BMSCs undergoing chondrogenesis in peptide hydrogels exhibit a very different 
pattern of glycosylation than adult chondrocytes in native tissue. 
The exact mechanisms whereby cells control CS chain length and sulfation pattern 
are still under study. TGF-β has been shown to affect CS-GAG synthesis; for example, 
TGF-β-stimulated fibroblasts produced elongated CS-GAG chains. In our recent study 
[60] in which animal-matched articular chondrocytes and BMSCs from immature or adult 
equines were cultured under identical conditions for 3 weeks in the same peptide 
hydrogel and in the same (TGF-β1-containing) medium, the BMSCs produced longer 
GAG chains than the animal-matched chondrocytes. This observation suggests that 
longer GAG chains are not just a result of TGF-β stimulation, but also a reflection of cell 
type. Since the GAGs contribute to the stiffness of cartilage, and proteolytic loss of 
protein-bound GAGs is a major characteristic of osteoarthritis, the BMSC-aggrecan 
would appear to have a more favorable GAG structure for cartilage mechanical function 
than the adult cartilage-aggrecan. 
A major finding in the present study was the demonstration that BMSC-aggrecan 
was demonstrably stiffer in nanomechanical compression than cartilage-aggrecan. The 
BMSC-aggrecan population had a larger average core protein length; thus, its pattern 
height (Figure 6-5c,d) and tip-substrate separation distance were larger than that of 
cartilage-aggrecan at the same normal force and ionic strength (Figure 6-5e,h). In order to 
compare their intrinsic stiffness independent of aggrecan dimensions, the force-distance 
curves were converted to curves of stress versus DMMB-measured sGAG concentration 
(Figure 6-6). Upon compression by the AFM tip, which increased sGAG concentration 
under the tip, the BMSC-aggrecan exhibited larger compressive stress. The macroscopic 
compressive moduli of bulk cartilage are known to correlate well with the concentration 
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of specific ECM constituents [3,115] such as collagen and GAG; and the correlation with 
GAG is ascribed to sGAG fixed charge density [3]. However, our observation indicates 
that at the nanoscale, not only the constituent sGAG charge density, but the molecular 
structure and dimensions of the GAGs can affect compressive stiffness. The longer 
disaccharide chains of BMSC-aggrecan may result in more intermolecular entanglement, 
steric and stronger excluded volume effects during deformation. In addition, electrostatic 
interactions between highly charged, closely-spaced rod-like chains are known to cause 
higher and more nonlinear increases in repulsive stress compared to that caused by 
compression of spatially homogeneous densities of fixed charge [5,97]. These 
phenomena may be particularly important in localized regions such as the 
microenvironment of cells, e.g. the pericellular matrix, which can be stimulated by 
mechanical forces. It also suggested that the stiffer BMSC-produced constructs in 
comparison with the chondrocyte-produced constructs we reported previously [60] may 
not only  due to the more total matrix content of the BMSC construct, but also due to the 
longer GAG chain and core protein length of BMSC-aggrecan . The greater stiffness of 
BMSC-aggrecan is also an attribute of immature native aggrecan [60] and may be 
advantageous to cartilage repair.  
Taken together, the nanomechanical properties of adult BMSC-peptide aggrecan 
appear superior to that of adult native cartilage aggrecan. Adult BMSCs are thus a 
promising cell candidate for cell-based tissue engineering for cartilage repair and 
regeneration. Of course, additional challenges must be met to achieve successful cartilage 
repair in vivo, including the assembly of an appropriate collagen architecture and the 
synthesis and assembly of other matrix macromolecules to enable integration with the 
surrounding tissues. The combined methodologies utilized here can be applied to 
optimize the cell source and culture for engineering desired ECM assemblies. The 
detailed structure and nanomechanical properties of aggrecan and other ECM molecules 
can provide insights into the molecular determinants to the integrity and functionality of 
cartilage repair. 
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Chapter 7  
Concluding Remarks 
With atomic force microscopy (AFM) techniques, the ultrastructure and nanomechanical 
properties of aggrecan from native cartilage and engineered cartilage are examined. AFM 
single molecule imaging enables the characterization of aggrecan intra- and inter-
molecular structure and conformation via direct visualization. The apparent core protein 
length (i.e., trace length) of aggrecan was found to increase with the presence of 
glycosaminoglycan (GAG) chains, possibly due to the electrostatic repulsion and steric 
forces between the negatively charged GAG chains. The extension ratio (end-to-end 
distance divided by trace length) of aggrecan was found to decrease with increasing 
aggrecan areal density. The conformation of aggrecan could be important determinants of 
its physical properties. Via direct visualization, the synthetic alterations on aggrecan 
structure were measured from the full-length aggrecan (i.e., newly synthesized aggrecan) 
subpopulation independently of proteolytic degradation. The full-length newborn human 
aggrecan was found to have longer GAG chains and a longer core protein trace length 
than the full-length adult human aggrecan. The newborn human aggrecan also exhibited 
larger stress, measured by high resolution force microscopy, than the adult human 
aggrecan at the same GAG concentration. This finding implied that at the nanoscale, not 
only the constituent sGAG charge density, but also the molecular structure and 
dimensions of the GAGs can affect the compressive stiffness of aggrecan. 
Aggrecan synthesized by equine bone marrow stromal cells (BMSCs) seeded in 
peptide hydrogels were found to have longer GAG chains than the animal-matched 
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chondrocyte produced aggrecan in the same system. When compared to aggrecan from 
adult equine native cartilage, the aggrecan produced by adult equine BMSCs seeded in 
peptide hydrogels had GAG chain length, sulfation pattern and nanomechanical 
properties characteristic of young cartilage aggrecan. The results suggest that BMSCs are 
promising cell candidates for cartilage tissue engineering. 
The methodologies presented in this thesis can be further applied to study other 
matrix molecules in cartilage. They interact with aggrecan and collagen and are 
responsible for the organization of the matrix assembly [7]. For example, collagen fibril 
formation is regulated via a number of extracellular matrix proteins, such as the small 
leucine rich repeat protein family, exemplified by decorin, biglycan, fibromodulin and 
lumican as well as the thrombospondins, the matrilins and many others. Many of these 
molecules remain bound at the surface of the completed fibril thereby providing the 
interactions with other components of the matrix (Figure 7-1). The assembly and 
properties of the collagen network are thus regulated by these proteins which can be 
expressed at different times and at different relative amounts. Presently we have limited 
information on the fine details of this regulation. The AFM methodologies can be adapted 
to elucidate the structure and interaction between these molecules. Understanding the 
basic mechanisms involved in forming complex cartilage matrix properties may lead to a 
treatment for damaged cartilage or improve the properties of tissue engineered cartilage. 
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Figure 7-1: Schematic illustration of molecular constituents in cartilage and their 
arrangement into large multimolecular assemblies [7]. 
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Appendix A  
Nanomechanical Properties of 
Aggrecan from Bovine and Human 
Cartilage of Different Ages 
In this appendix, the nanomechanical properties of aggrecan from different age of human 
and bovine are compared. The nanomechanical testing on bovine aggrecan was 
conducted by Dean and Han and the corresponding results were reported in Han’s thesis 
Appendix C.  
A.1 Introduction 
Cartilage tissue is characterized by high stiffness and strength and some articular 
cartilage, the tissue on the surface of load bearing joints, able to withstand up to 
mechanical loads encountered over many years of life, ideally with little damage. The 
tissue’s dense extra-cellular matrix (ECM) responsible for these mechanical properties is 
comprised mostly of water (60-80%) and macromolecules, such as collagen type II (60% 
dry weight) and proteoglycans (35% dry weight). The mechanical properties of the tissue 
are directly related to the structure and interactions of these various macromolecules. 
Proteoglycans are thought to be responsible for ~50% of the compressive stiffness of the 
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tissue. Of the various proteoglycans found in cartilage, the most abundant (50-85%) is 
aggrecan. It is distinguished by its ~100 highly negatively charged chondroitin sulfate 
glycosaminoglycan (GAG) chains attached to a core protein in a bottle brush-like 
structure. GAG length, spacing, and sulfation are known to vary with age, source, and 
location [4,56,133]. These differences in structure contribute to the wide variations in 
observed biomechanical properties of cartilage [134]. This study focuses on the 
molecular-level compressive properties of aggrecan taken from two different bovine 
tissues, fetal epiphyseal and mature nasal. 
Previously, individual aggrecan from two different bovine cartilages, fetal epiphyseal 
(FE) and mature nasal (MN), were imaged via atomic force microscopy (AFM) [4]. The 
differences on the architectural features of these two samples are distinct. The FE 
aggrecan has significantly longer core protein trance length LCP, longer GAG chain trace 
length LGAG and smaller GAG spacing. The molecular stiffness of the two different 
aggrecan, characterized as the persistence length LP, from the AFM images of isolated 
aggrecan molecules deposited on the planar mica surfaces were quantified. Both the core 
protein and the GAG chains were found to have significantly shorter persistence length in 
the MN compared to the FE. A similar comparison was made in Chapter 3 of human 
aggrecan from donors of different ages. The newborn human (NH) aggrecan shows 
architectural features similarity to the FE aggrecan with significant longer LCP, LGAG, and 
LP than the adult human (AH) aggrecan. 
We previously reported the nanoscale compressive interaction forces between 
opposing FE aggrecan in an end-grafted layer, and found that the measured normal stress 
at near physiological ionic strength (IS) of 0.1M NaCl increased sharply at aggrecan 
densities under the tip of ~40-50 mg/ml, which corresponds to an average 3D-GAG 
spacing of ~4-5 Debye lengths [5]. This characteristic spacing is consistent with the onset 
of significant electrostatic interactions between GAG chains of opposing aggrecan 
molecules at physiological IS. The objective of this study was to test the hypothesis that 
the nanomechanical properties of MN and AH aggrecan are very different from those of 
FE and NH aggrecan, as suggested by the measured age-related differences in GAG 
length, spacing, and sulfation. 
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A.2 Methods 
A.2.1.  Aggrecan Purification 
Aggrecan extraction and purification was previously described [4,35]. In brief, bovine 
aggrecan was from fetal bovine epiphyseal and mature bovine nasal; human aggrecan 
was from one newborn and one 38 year-old adult articular cartilage where there was no 
microscopic evidence of arthritic disease and no joint damage. Guanidine HCl extraction 
followed by dissociative CsCl density gradient centrifugation was performed to obtain 
the A1A1D1D1 fractions of bovine aggrecan and D1D1 fractions of human aggrecan. All 
samples were dialyzed exhaustively against water, lyophilized, dissolved in water, and 
stored at -20 °C in 1 mg/ml aliquots 
A.2.2.  AFM Sample Preparation 
Purified aggrecan were end-functionalized by reaction with 1mM 3,3’-
dithiobis(sulfosuccinimidyl propionate) and 0.1mM dithiothreitol (Pierce) for 1 hour. 
Excess reactants were removed by spinning (3500rpm) overnight with a centrifugal filter 
(Centricon, Millipore, 10kDa cutoff). The functionalized aggrecan and OH-terminated 
self-assembled monolayer (OH-SAM, 11-mercaptoundecanol HS(CH2)11OH, Aldrich) 
were patterned onto gold substrates with microcontact printing as previously described 
[5]. The densely packed, chemically end-grafted aggrecan was then patterned in 
micrometer-sized hexagon-shaped areas surrounded by OH-SAM. Prior to 
nanomechanical measurements, the surfaces were thoroughly rinsed with deionized water. 
The aggrecan packing density within the hexagons, measured via dimethylmethylene 
blue (DMMB) dye assay [89], was ~8 mg/m2 (~1 aggrecan per 25nm × 25nm, equivalent) 
for all aggrecan samples. 
A.2.3.  Nanomechanical Testing 
Cantilevers with micron-sized gold-coated silica colloids (BioForce Nanosciences, probe 
tip radius, Rtip = 2.5 μm, spring constant, k ~ 0.12 N/m) were functionalized with a OH-
SAM by immersion in 3mM HS(CH2)11OH (Aldrich) in ethanol for 48 hours.  
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A Multimode Picoforce Nanoscope IV atomic force microscope (AFM, Veeco) was 
used to measure the height of the aggrecan monolayer as well as the force between the 
aggrecan layer and neutral probe tip. The height of the aggrecan monolayers was 
measured using contact mode AFM in different ionic strength (IS) solutions (0.001M-1M 
NaCl, pH ~ 5.6) at different compressive loads (~0-80 nN). The normal compressive 
force versus tip-sample separation distance between the identical OH-SAM probe tip and 
aggrecan layers was also measured using high resolution force spectroscopy (HRFS) [135] 
at 0.1M NaCl, pH ~ 5.6. To obtain absolute values of the tip-surface separation distance, 
D, the distance axes were offset by the compressed height of aggrecan measured with 
known normal forces in the contact mode.  
F-D curves were converted to normal stress vs. normal molecular strain: stress was 
calculated as the force per unit surface area using the surface element integration method 
[120], a variant of the Derjaguin approximation, and strain was 1 – (D / Do), where Do, 
the uncompressed aggrecan layer height, was set equal to the distance at which the 
measured normal force increased above noise level (~ 20 pN) in the HRFS experiment 
minus 5× the Debye length (κ-1 ~ 1nm) [136]. 
A.3 Results 
The heights of all aggrecan decreased nonlinearly with increasing IS and increasing 
compressive force (Figure A-1). The heights of FE and NH aggrecan attained a maximum 
of 320 nm and 210 nm, respectively, at 0.001M under low load (~0 nN) and a minimum 
of 31 nm and 15 nm, respectively, at 1M under high load (~80 nN) (Figure A-1a,c). The 
heights of MN and AH aggrecan attained a maximum of ~200 nm at 0.001M under low 
load and a minimum of 20 nm and 10 nm, respectively at 1M under high load (Figure A-
1b,d). The MN aggrecan required lower normal force than the FE aggrecan to compress 
to the same amount relative to its contour length, LCP. At 0.1M NaCl, the MN 
compressed to 0.95 LCP whereas the FE aggrecan compressed to 0.66 LCP at ~50 nN 
compressive force.  
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Figure A-1: Height versus normal force for chemically end-grafted aggrecan monolayers 
at different ionic strengths (0.001M – 1M NaCl); (a) fetal epiphyseal; (b) mature nasal 
aggrecan; (c) newborn human; (d) adult human. 
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The forces measured using HRFS were nonlinear repulsive and started at D for all 
types of aggrecan (Figure A-2). Force versus distance curves measured by HRFS with 
OH-SAM colloidal tips for the FE aggrecan was very similar to what has already been 
reported [5]. The force-distance data of other types of aggrecan showed same decrease in 
force with increase in IS (Figure C-4) as the FE aggrecan. However, the FE and NH 
aggrecan showed an earlier force incensement at larger Do.  
 
 
Figure A-2: Force-distance curves (loading) of (a) FE (b) MN (c) NH (d) AH aggrecan 
monolayers. Each curve is an average of 15 curves for the bovine aggrecan and 30 curves 
for the human aggrecan (std < 0.02 nN)  
 117
Stress increased nonlinearly with strain much more sharply for the FE than the MN 
aggrecan (Figure A-3a). At strain= 0.5, the measured stress was >10× larger for the FE 
(~5 kPa) compared to the MN aggrecan (~0.3 kPa). A similar trend was observe in the 
comparison of NH and AH aggrecan, which the stress of NH increased more sharply 
compared to AH (Figure A-3b). 
 
Figure A-3: Molecular stress versus strain of a single aggrecan layer being compressed 
by an OH-SAM functionalized colloidal tip in 0.1 M NaCl aqueous solution. (a) FE and 
MN aggrecan layers; (b) NH and AH aggrecan layers. 
A.4 Discussion 
All types of aggrecan were end-grafted onto gold substrates at similar packing densities 
(within the physiological range of 20-80mg/ml [137]), thus allowing for direct 
comparison of their nanomechanical properties. The FE and NH aggrecan layer was 
(a) 
(b) 
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stiffer than the MN and AH aggrecan for all IS tested since more force was required to 
compress the FE/NH layer to the same height relative to its contour length than MN/AH 
aggrecan. This observation is likely due to the fact that the FE/NH aggrecan has both 
increased electrostatic and nonelectrostatic (steric and entropic) repulsive interactions 
compared to the MN/AH. The increased electrostatic forces come from the increased 
charge per GAG chain of FE/NH compared to MN/AH aggrecan, as well as the smaller 
GAG-GAG molecular spacing along the core protein. The increase in nonelectrostatic 
interactions may arise from the larger dimensions of the aggrecan (i.e., core protein and 
GAG trace length) and also the smaller GAG-GAG molecular spacing along the core 
protein. This is supported by the fact that the FE/NH aggrecan appears to be stiffer than 
the MN/AH at 1M NaCl when most of the electrostatic interactions are shielded. 
Although FE/NH aggrecan is markedly stiffer than MN/AH aggrecan at near 
physiological conditions (0.1M NaCl, Figure A-3), they both exhibit similarly shaped 
nonlinear nanomechanical stress-strain behavior. In cartilage tissue, aggrecan molecules 
are precompressed, occupying less volume than in the dilute extended conformation 
[138], even at zero tissue-level strain. Therefore it is difficult to know what value on the 
molecular stress-strain curve corresponds to tissue strain in vivo. However, these directly 
measured molecular-level stress-strain curves are similar to previous results on swelling 
pressure of proteoglycan solutions [46,139]. This study further confirms that the mature 
aggrecan is more compressible than the immature aggrecan.  
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Appendix B  
FACE Analysis of Aggrecan 
Produced by Animal-matched 
Chondrocytes and BMSCs 
The sulfation patterns of chondroitin sulfate (CS) GAGs have been studied previously as 
a characteristic of animal age, GAG chain termination, tissue differentiation and 
development [21,131,132]. It has been shown that the ratio of 6S- and 4S-sulfated CS is 
higher in the adult cartilage tissue than in the skeletally-immature and growing cartilage 
[122,123]. For GAG produced in vitro by synovium-derived mesenchymal stem cells 
seeded in collagen gel, the 6S to 4S ratio was found to increase progressively during 
culture [140]. In Chapter 6, we have compared the sulfation patter of the CS produced by 
adult bone marrow stromal cells (BMSCs) to that of CS extracted from adult cartilage. In 
contrast to the adult cartilage CS GAG which has predominant 6S-sulfated CS, adult 
BMSC-produced CS has approximately equal amount of 4S- and 6S-sulfate CS. 
Here the sulfate patterns of CS produced by foal chondrocytes, foal BMSCs and 
adult chondrocytes in peptide gel cultured with or without TGF-β1 are compared. The 
foal chondrocytes cultured with/without TGF-β1 produced CS with 1.5~2.5 4S-to-6S 
ratio. The foal BMSCs with TGF-β1 stimulation produced the highest ratio (>3) of 4S to 
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6S. The adult chondrocyte-produced CS had the lowest 4S-to-6S ratio among all cell-
produced CS in vitro and are closest to the ratio of the adult cartilage extracted CS. 
 
 
 Figure B-1: Fluorescence-assisted carbohydrate electrophoresis (FACE) analysis of CS 
GAG produced by equine chondrocytes (Chd) and BMSCs seeded in peptide hydrogel 
(KLDL) for 21 days. Di6S 
Table B-1: FACE analysis of CS sulfation pattern 
Sample # 1 2 3 4 5 6 7 8 9 10 
Sample 
Description 
Foal 
Chd 
Foal 
Chd 
Foal 
Chd 
TGF-β 
Foal 
Chd 
TGF-β 
Foal 
BMSC
TGF-β 
Foal 
BMSC
TGF-β 
Adult 
Chd 
TGF-β 
Adult 
Chd 
TGF-β 
Adult 
Chd 
TGF-β 
Adult 
Cartilage 
ΔDi4S: ΔDi6S 2.5 1.5 1.7 1.5 3.1 3.2 1.1 1.4 0.8 0.5 
Std      1       2       3        4       5       6    Std      7       8       9       10 
Foal Chd Foal Chd
+ TGF-β
Foal BMSC
+ TGF-β
Adult Chd
+ TGF-β
Adult 
Cartilage 
ΔDi4S 
ΔDi6S 
ΔDi0S 
ΔDiHA 
ΔDi4S
ΔDi6S
ΔDi0S
ΔDiHA
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Appendix C  
Human Intervertebral Disc Aggrecan 
Intervertebral disc (IVD) aggrecan of a 37 year-old human was received from Dr. 
Roughley. The aggrecan samples were extracted from the outer annulus fibrosus (OAF), 
inner annulus fibrosus (IAF) and nucleus pulposus (NP) of the IVD and purified as D1D1 
density centrifugation preparations. Each sample is about 5mg of freeze-dried aggrecan.  
Since the aggrecan populations are from 3 distinct extracellular matrixes (ie. OAF, 
IAF and NP; Figure C-1a), they may possess different architectural features due to the 
variations in the aggrecan synthesis and proteolytic activities in those matrixes [141]. The 
3 aggrecan populations showed different polydispersity and electrophoretic mobility on 
the agarose gel (Figure C-1b). The polydispersity of the aggrecan population is likely due 
to the heterogeneity in aggrecan core protein length and GAG chain length. Among the 3 
populations, NP aggrecan exhibited the narrowest size distribution and relatively higher 
mobility (ie. larger molecular weight) than the other two. IAF had a similar width of 
distribution to OAF, but contained a major subpopulation with high mobility as seen in 
the NP aggrecan. 
AFM images showed abundant aggrecan fragments in all samples, which is 
consistent with the accumulation of proteolytic degradation products in the disc. While 
all aggrecan samples have globally similar structure, the OAF aggrecan possessed shorter 
GAG chain than the other two. The differences in GAG chain length are likely due to the 
type of cells that synthesize the aggrecan. Cells from NP, IAF, and OAF show distinct 
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morphology and rate of sulfate incorporation when cultured in identical in vitro 
environment [142]. Cells from NP have the highest rate in sGAG production, implying 
the highest rate in aggrecan production. Reports have shown the a higher aggrecan 
synthesis rate may result in the synthesis of longer GAG chains due to the longer time for 
the core protein post-translational process [77,78,119]. More quantitative analysis on the 
AFM images are needed to further compare the structural differences between the 3 
aggrecan populations.  
 
Figure C-1: (a) A schematic showing the vertical cross-section of the adult human IVD. 
Adapted from [143]. (b) Agarose-gel electrophoresis of outer annulus fibrosus (OAF), 
inner annulus fibrosus (IAF) and nucleus pulposus (NP) aggrecan. 
OAF IAF NP 
Calcified endplate
Indistinct inner AF
 
Fibrous NP
Outer AF
Vertebral bone
(+) 
(–) 
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Figure C-2: AFM images of aggrecan from (a-b) NP (c-d) IAF and (e-f) OAF of a 37-
year-old human IVD 
a   NP b  NP 
c  IAF d  IAF 
e  OAF f  OAF 
400 nm 
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Appendix D  
Bovine Aggrecan from Commercial 
Source and Porcine Aggrecan from 
Intervertebral Disc 
Aggrecan extracted from bovine nasal septum was purchased from MP Biomedical 
(Santa Ana, CA). The aggrecan is isolated under dissociative conditions by finely 
mincing the tissue at low temperature in the presence of protease inhibitors. The product 
is then lyophilized from distilled water containing no preservatives. The lyophilized 
aggrecan powder was resuspended with DI water and imaged via AFM. Compared to the 
A1A1D1D1 bovine nasal aggrecan used in [4], the MP aggrecan sample contained 
mostly fragments of aggrecan and some non-aggrecan molecules (Figure D-1a). When 
analyzed with an S-1000 chromatography column, the MP aggrecan showed a single 
peak with molecular weigh larger than 2 MDa. When mixed with hyaluronic acid (HA) 
for 4 days, MP aggrecan formed aggregates of size 15 MDa (Figure D-1b). 
The purified porcine aggrecan from the intervertebral disc was recireved from the 
Skeletal Biotechnology Lab in Hebrew University. The structure of porcine aggrecan 
(Figure D-2) is similar to the aggrecan from other species (bovine, human and equine) 
characterized previously. The core protein has numerous GAG chains attached. The G1 
and G3 domains of aggrecan are identified in the AFM images. 
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Figure D-1: Bovine nasal aggrecan purchased from MP Biochemical. (a) AFM images of 
MP aggrecan (b) S-1000 chromatography profiles of MP aggrecan monomers (200 μg) 
and MP aggrecan aggregates with HA. 
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Figure D-2 : AFM images of porcine aggrecan. The globular domains of aggrecan are 
identified and indicated with arrows. 
 
400 nm 200 nm
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Appendix E  
Protocol for AFM Imaging Aggrecan 
Monomer  
E.1 APTES-mica 
1. Mix 3 µl of APTES (3-aminopropyltriethoxysilane, Sigma) with 30 ml MilliQ 
water (0.01% v/v). Shake gently by inverting the vial a few times. 
2. Cleave mica (1cm × 1cm) with paper tape in a bio-hood. Make sure the cleaved 
plane comes off cleanly in one piece. Place the cleaved mica in a close container 
with the cleaved plane side up. Do not touch the cleaved plane. 
3. Immediately after cleavage, place 50 µl (or enough to cover the entire surface but 
not spill off) of the 0.01% APTES solution on the cleaved mica. Keep in a closed 
container with water to minimize the evaporation of the solution. (eg. Use a 
pipette tip box filled with water in the bottom. Mica can be place on the divider in 
the middle.) Incubate for 30 minutes at room temperature. 
4. Rinse gently in a stream of MilliQ water for ~10 seconds (~200 µl). Blot on edge 
of the mica on a piece of filter paper to dry. (Nitrogen drying optional.) 
5. Store in a closed container to prevent dust. Use the prepared mica in the same day. 
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E.2 Aggrecan Monolayer 
1. Thaw the frozen aggrecan solution at room temperature.  
2. Dilute the aggrecan solution with MilliQ water to desired concentration and 
volume (10~100 µg/ml, 50 µl/mica). Mixed the diluted sample well by pipetting 
up and down a few times. 
3. Incubate 50 µl of the diluted aggrecan solution on mica in a closed container with 
water at the room temperature. The incubation time can range from 20-60 minutes, 
depends on the desired final monolayer density of aggrecan.  
4. Rinse gently in a stream of MilliQ water for ~10 seconds (200 µl). Blot on edge 
of the mica on a piece of filter paper to dry. 
5. Store in a closed container to prevent dust. Image when the sample is completely 
dry (> 4 hours). 
E.3 AFM Imaging 
E.3.1.  Choices of AFM Probes 
1. SSS-NCHR, SuperSharp, Tapping Mode AFM Probe, Reflex Aluminum, length: 
125 μm, force constant: 42 N/m, resonance frequency: 330kHz 
(NANOSENSORS) 
2. SSS-NCHR, SuperSharp, Tapping Mode AFM Probe, Reflex Aluminum, length: 
225 μm, force constant: 48 N/m, resonance frequency: 190kHz 
(NANOSENSORS) 
E.3.2.  Start the Instrument 
3. Open the Nanoscope Program on the computer.  ALWAYS open the program 
before anything else. 
4. Turn the Controller on. 
E.3.3.  Setting up for Imaging 
1. Select the appropriate piezo. 
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a. E scanner: x-y direction: 10 µm; z-direction 2.5 µm 
b. J scanner: x-y direction: 100 µm; z-direction 5 µm 
2. Glue the mica sample on the magnet with adhesive tabs. Place the magnet on the 
top of the piezo tube. Use tweezers to handle the samples and avoid touching the 
sample surface. 
3. Place the AFM head on the piezo and attach the springs to the head. Hold the 
head tightly while you do this. Make sure it is ALWAYS securely attached.  
4. Raise the head from the sample so you do not damage the tip and sample when 
you slide in the tip holder. 
5. Select a cantilever. Carefully slide the chip into the holder until you hit the groove. 
Make sure the cantilever chip is right-side up (the step around the chip should be 
on the bottom.) 
6. Place the holder into the head at a 45º angle to the surface (or at an angle so the 
holder and cantilever don’t hit the stage.) 
7. Switch the mode to AFM.  Plug in laser and align the laser onto the tip of the 
cantilever with the optical microscope. Maximize the sum. Set the vertical and 
horizontal difference to 0V. 
8. Switch the mode to TMAFM. 
9. Placing the AFM on a tripod during imaging improves the image quality 
significantly. However, use extreme caution when setting the AFM on the tripod.  
E.3.4.  Setting on the Nanoscope Program 
1. Go to auto tuning mode by clicking the tuning icon to find the cantilever resonant 
frequency. Set peak offset to 3-5%. Click Auto Tune bottom.  You should see an 
amplitude profile with one clear peak.  
2. Go back to image mode. 
3. Check the selected scanner: Go to MICROSCOPES > SCANNER > E or J 
4. Check the selected profile: Go to MICROSCOPES > SCANNER > Tapping 
Mode 
5. Other parameters: 
Scan Controls 
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a. Scan size : 2 µm 
b. Aspect ratio 1:1 
c. X offset: 0 nm 
d. Y offset: 0 nm 
e. Scan angle: 0 
f. Scan rate: 0.5~1 Hz 
g. Samples/line: 256 (pre-scan)  512 (high quality image) 
h. Slow scan axis: Enabled 
Feed back Controls 
a. SPM feedback: Amplitude 
b. Integral gain: 0.3~0.5 (Make sure it is low enough to prevent feedback 
oscillation) 
c. Proportional gain: 0.5 
d. Amplitude setpoint: 0.6~1 (For tapping mode, the lower the value, the 
greater contact force on the tip. Use a larger value to prevent tip damage, 
but a too large value will make the tip lose contact with the surface.) 
e. Drive frequency: should be determined by Auto Tune 
f. Drive amplitude: should be determined by Auto Tune 
Other Controls 
a. Microscope mode: Tapping 
b. Z limit: according to the piezo 
c. Units: Metric 
d. Engage Setpoint: 1~0.8 (the lower the value, the greater the engage force. 
Use a larger value to prevent tip damage, but a too large value will make 
the tip lose contact with the surface later on) 
e. Parm update retract: Disabled 
Channel 1 
a. Data type: Height 
b. Data scale: 5 µm 
c. Line direction: trace 
d. Scan line 
 133
e. Realtime planetfit: Line 
f. Offline planefit: None 
Channel 2 
a. Data type: Amplitude 
b. Data scale: 1 V 
c. Line direction: Retrace 
d. Scan line 
e. Realtime planetfit: Line 
f. Offline planefit: None 
2. Press the Engage icon to bring the tip to the sample surface. 
3. Once the tip is engaged, you should hear a beep sound and see images appear. 
4. During imaging, pay attention to the piezo Z center position. Make sure it doesn’t 
exceed ±150V. 
5. Avoid scanning any large dust by offsetting the imaging area with the software or 
disengaging and adjusting the scanning area with the adjustment screws. Do NOT 
use the adjustment screws unless the tip is disengaged. 
6. Click the Capture bottom to capture an image. The software will capture the next 
complete image. If any parameters have been changed after the capture function is 
activated, the capture function will be held until the next frame. 
7. When you are done or want to move another area on the sample, disengage the tip. 
E.3.5.  Clean up 
1. Disengage the tip from the sample. 
2. Unplug the laser. 
3. Raise the tip from the sample so you do not damage the tip and the sample when 
you take out the holder. 
4. Take out the cantilever chip from the hold and put it back in the tip box. 
5. Detach the springs from the head. 
6. Put the sample away. 
7. Turn off the controller. 
8. Close the software. 
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Appendix F  
Protocol for High Resolution Force 
Measurement of Aggrecan 
F.1 Thiol-Functionalization of Aggrecan Core 
Protein 
1. Prepare 2mL 1mg/ml aggrecan aliquot (or .5mg/ml) 
2. Add ~100μL dithiobis(sulfosuccinimidyl propionate) (DTSSP, 6mg/0.5ml) to the 
aggrecan solution. Wait for 1hr. 
3. Add ~200μL dithiothreitol (DTT, 3mg/1ml) to the aggrecan solution. Wait for 1hr. 
4. Filter the aggrecan solution with a 100,000 MW cutoff centrifugal filter device at 
speed between 3500~4000 rev/min for ~5-6 hrs to remove the reactant. 
a. Turn the centrifuge Power on. Se the Brake off. 
b. Put samples and dummy tubes, if necessary, in the rotor and tighten the 
rotor cap in counter-clockwise direction 
c. Lock the lid 
d. Set time to hold and speed between 3500~4000 rev/min. If rotor is not 
balanced, speed will not go up. 
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e. Take out the filtrate tube, reverse the device, centrifuge w/ same speed for 
another 30min to concentrate the remained aggrecan solution into the 
sharp-end tube. 
f. The concentrated aggrecan solution will be ~200μl, very viscous. 
5. Dilute the aggrecan solution to desired concentration (~1mg/ml) with MilliQ 
water. 
6. Freeze the samples in the -80ºC freezer to store. 
F.2 OH-SAM Coated Stamp and AFM Probe 
1. Make 4mM OH-SAM solution by Dissolving 25 mg 11-mecaptoundecanol 
(HS(CH2)11OH) powder in 40 mL ethanol (4mM). Vortex until the powder is 
fully dissolved. 
2. Rinse gel boxes with ethanol. Blow dry with Nitrogen and fill with 4mM OH-
SAM. 
3. Rinse stamps/tips with ethanol. Place tips/stamps in the gel boxes with the right-
side up. 
4. Make sure the stamps/tips are fully immersed in the OH-SAM solution 
F.3 Micro-contact Printing of OH-SAM and 
Aggrecan Substrate 
1. Make Piranha solution (place 2ml hydroproxide H2O2 in 6ml sulfuric acid H2SO4) 
in glass disc. Make sure the two chemicals are well mixed. Use caution when 
handling H2O2 and H2SO4. 
2. Place the Au coated silicon substrate (1 cm × 1 cm) in the Piranha solution with 
tweezers. Make sure not to scratch the gold surface. Wait for 20 min. 
3. Rinse the gold surface with DI and blow dry with Nitrogen. 
4. Repeat step 1 to 3. Check if there are a lot of bubbles forming on the gold surface. 
If not, the solution may not be well mixed and the cleaning is not effective. 
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5. Right before Piranha clean finishes, take out PDMS micro stamp form OH-SAM. 
Put it on filter paper with the stamp side facing up. Make sure there is no water 
drops on the stamp side. 
6. Stamp the gold surface with the micro stamp. Use tweezers to bring the stamp in 
contact with the gold surface. Once in contact, gently press the stamp to ensure 
uniform contact. Wait for 2 mins. 
7. Remove the stamp. Rinse the gold surface with ethanol and DI. Blow dry with 
Nitrogen. 
8. Place 50 μl aggrecan solution onto the gold surface. Incubate in a humidity 
controlled environment (eg. a air tight box with water) for ~48 hrs. 
9. Rinse the micro stamp with ethanol and DI. Put it back to OH-SAM solution. 
10. OH-SAM solution needs to be changed every other time. 
11. Piranha waste goes to the empty H2SO4 bottle. 
F.4 High Resolution Force Microscopy 
F.4.1.  Setup 
1. Setup the Nanoscope IV AFM with the PicoForce piezo.  
2. Open the Microscope software. Turn on controllers: AFM (lower one +  FC chip 
plugged in); PicoForce (on the back of monitors) 
3. Click the Real Time button  
4. Select: Scan Triple, PicoForce, Thermal Tune 
F.4.2.  Load Tip and Sample 
1. Rinse the liquid cell tip holder with ethanol.  Blow dry with Nitrogen. 
2. Pick up an AFM tip from the HO-SAM solution. Use a syringe with an attached 
filter to rinse the tip with ethanol, DI water and 0.001M NaCl. 
3. Insert the tip into the tip holder. (Use the 0.06 kN/m for aggrecan, long and thin 
one) 
4. Rinse the sample with DI water. Blow dry with a gentle Nitrogen stream. 
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5. Place the sample on a filter paper 
6. Use sharp tweezers to pick a little amount of super glue onto the magnet. 
7. Mount the sample onto the magnet and wait for ~ 1 min or until the glue cures. 
8. Load the sample onto AFM 
9. Place 3 drops of 0.001M NaCl solution on the sample. 
10. Load the AFM head. 
11. Raise the head by toggling “tip up” (To prevent the tip hitting the sample.) 
12. Insert the tip holder. Check if the tip is immersed in the NaCl solution drop. If not, 
bring the tip closer to the substrate with caution. 
13. Find the tip position with an optical microscope. Use paper method to align the 
laser at the tip of the cantilever (sum: ~6). 
F.4.3.  Pre-image 
In Scan Triple mode: 
1. scan size: 30μm  
2. scan rate: 1Hz 
3. samples/line: 256 
4. gain: 0.2/0.3 
5. angle: 90 
6. deflection setpoint: 0V 
7. Find good shape hexagon  
F.4.4.  Height vs. Force Measurement (2D imaging) 
In Scan Triple mode: 
1. Offset to a good scanning area. 
2. Change Aspect ratio to 32 (8 lines) 
3. Set Real time fit to Line 
4. Disengage 
5. Adjust the photodiode position VERT on the AFM machine to ~-3.10V 
(disengage deflection baseline) 
6. Set setpoint in the software to -3.5V (Scan with ~0 force) 
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7. Click the Engage button 
8. Take 16 images with setpoints from -3.5 to 2V (Decrease gain gradually with 
increasing setpoint) 
9. Disengage, record the VERT value (final deflection baseline) 
F.4.5.  Force vs. Displacement Measurement (1D indentation) 
1. Engage in scan triple mode, center at a good area 
2. Click PicoForce mode 
3. Set Ramp: 1~2μm; 1Hz; 512 
4. Set Trig threshold: 7V (“Relative” to baseline; trig threshold + BL < 5V) 
5. Click Capture continuous 
6. Press “Single” 10 times (Capture 10 images) 
7. Switch to another position (same hexagon) 
F.4.6.  Switch NaCl solution 
1. Detach the AFM head 
2. Blot dry the sample at the edge with filter paper while keeping the sample 
mounted on the AFM. 
3. Place a few drops of the new NaCl solution on the sample without spilling. Blot 
dry with filter paper. Repeat 3 times. 
4. Place 3 drops of the new NaCl solution on the sample. 
5. Use a twisted Kimwipes tips to absorb the leftover liquid in tip holder. 
6. Resemble the AFM head.  
F.4.7.  Deflection Sensitivity 
1. After the Force vs. Displacement experiment, move the tip position to a OH-SAM 
covered area (no aggrecan) 
2. Measure the Force vs. Displacement again in PicoFore mode 
3. In the bottom left graph (Def vs. Z). Bring the lines from the edges and measure 
the deflection sensitivity. 
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F.4.8.  Thermal Tune 
1. Disengage. Set aspect to 1. Move tip up 
2. Adjust VERT to 0 
3. Press thermal tune 
4. Fit peak 
5. Record spring constant 
6. Note: Force [nN] = spring constant [N/m] × deflection [V] ×  deflection 
sensitivity [nm/V] 
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Appendix G  
Protocol for Analysis of Aggrecan 
Aggregation with a Sephacryl S-1000 
Chromatography Column 
G.1 Sodium Acetate Column Buffer (0.5M, 500 ml) 
1. Dissolve sodium acetate 20.5g in ~400 ml DI water. 
2. Add 0.5 ml Triton (0.1% v/v)  
3. Add 0.1 g NaAzide (0.02% g/ml, toxic. Place the buffer in the fume food.) 
4. Use acetic acid to adjust pH to 6.8.  
5. Top off the solution with DI water to 500 ml. 
G.2 Molecular Weight Markers 
1. Phenol red ~354 Da, absorption @ 560 nm 
2. Dextran blue ~2MDa, absorption @ 560 nm 
3. DNA (Sigma D3664) 10~15 MDa (100 µg/ml) 
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G.3 Aggrecan Aggregate Samples 
1. Mix 10 µg HA and 1000 µg Aggrecan in 500 µl DI water (pH 7) or PBS. Incubate 
in 4°C for at least 48 hrs. 
2. Further purification of the aggrecan aggregates with CsCl density centrifugation 
in associate condition is optional.  
G.4 Packing S-1000 Column 
1. Assembly column parts (reservoir, column, valve). 
2. Mix S-1000 gel with glass rod in the original bottle and pour ~60ml in a beaker. 
(for a 1 × 45 column) 
3. Flood the column with DI water with valve closed. Accumulate 2-3 cm height of 
DI. Check leakage. 
4. Pour in S-1000 gel until the column is almost full. Open the valve to flow out DI 
water. Add more S-1000 gel. 
5. Use DI water to rinse S-1000 residue in the beaker and pour into the column with 
the valve open. 
6. Wait for the gel to precipitate, check water lever and measure flow rate. 
7. As the gel is packing, the water level of the column drops. Constantly add DI 
water to keep a few inches of water on the top of the gel while packing. (When 
adding water/buffer, tilt column to avoid bubbles) 
8. After 24 hrs or until the gel level stops dropping, use pipette to remove the excess 
gel. While removing the gel, keep a layer of DI on the tip of the beads (~3mm). 
9. Remove the reservoir. Use a pipette to top off the column with buffer. Measure 
flow rate (eg. 2.5 min 0.88g, 21ml/hr). 
10. Connect the pump tubing to the column. Adjust pump flow rate to match column 
flow rate (relative speed: 13 × 10). 
11. Run the buffer of 10 times the column volume through the column (eg. 35ml × 10 
≈ 350ml ≈ 16hr) 
12. Measure flow rate (eg. 0.264 ml/min). 
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13. Stop the pump. Close the valve. Cap the column and store in the fume food. 
G.5 Operation 
1. Use pipette to aspirate the buffer from the top of the column. Leave only 1mm 
buffer on the top of the gel. Avoid disturbing the gel while aspirating the buffer. If 
disturbance occurs, wait until the gel precipitates (should see a clear separation of 
the gel from the buffer)   
2. Carefully inject sample on the top of the column (For marker mixture: 150 µl 
phenol red, 150 µl Dexon, 100 µl 10µg/ml DNA; for aggrecan aggregate sample: 
300 µl, 200 µg sGAG). 
3. Open the valve and let the sample level drop to 1mm height above the gel. Close 
the valve. 
4. Add 200 µl × 5 buffer on the top (to wash off the sample residue). Aspirate the 
buffer. 
5. Top off the column with ~ 3ml buffer. Turn on the pump and the valve. Start the 
fractionator (0.5ml/valve, 1.92 min/valve, ~150 valves). 
6. Analyze the eluant using a spectrometer with proper dyes (aggrecan: DMMB dye; 
DNA: fluorescent dye).  
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Appendix H  
Guanidine Extraction and Aggrecan 
Purification 
Written by Paul Kopesky on February 29, 2008; Adapted from protocols developed by J 
Sandy and Anna Plaas. 
H.1 Materials: 
1. Guanidine HCl (4M) 
2. Sodium Acetate (100mM) 
3. Protease Complete Tablets (Roche) 
H.2 Procedures 
1. Make desired volume of 4M Guanidine HCl in 100mM Sodium Acetate buffer 
and adjust pH to ~7.2.  Rough guide: For tissue engineered plugs, make 1mL for 
every ~40mg of tissue wet weight with sGAG content of ~120ug (i.e. plug sGAG 
content is ~3ug/mg wet weight). I would double the amount of extraction solution 
if using native tissue instead of engineered samples. 
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2. Add appropriate fraction of protease complete tablet per manufacturer’s 
instructions. (Inhibits a broad range of proteases). 
3. Mechanically disrupt sample.  May use a scalpel to dice (works for tissue 
engineered plugs).  If using native cartilage tissue, may want to pulverize and 
homogenize. 
4. Add appropriate volume of combined solution samples as per step #1 above. 
5. Mix on shaker at 4C for 48hrs (probably excessive, but will maximize PG 
extraction) 
6. Spin for 0.5-1hr at ~16,000 x g in microcentrifuge at 4C. 
7. Transfer clarified supernatant to new tube and discard pellet. 
8. Add CsCl powder until solution density is 1.58g/mL.  Check density by weighing 
a known volume of solution. 
9. Transfer sample to an appropriate tube for ultracentrifuge and balance 
ultracentrifuge rotor exactly!! 
10. Spin as long and as hard as you can.  72hrs at ~500,000 x g should produce a 
good density gradient. 
11. Immediately at the end of the spin, carefully pipette fractions of the sample.  
Splitting 1mL into ~10 x 100uL fractions works well. Start by pipetting off the 
very top and working down the tube. Be aware that a hard pellet of CsCl may 
form at the bottom; the density gradient will likely still be sufficient for PG 
purification. 
12. Measure the density of the fractions as in step #8. 
13. Combine fractions based on density. D1>1.54g/mL; 1.46g/mL<D2<1.54g/mL 
(Roughly &White. JBC 255:217-224. 1980) 
14. Dialyze with 500 volumes of 1M NaCl for 12-24 hrs. 
15. Dialyze with 500 volumes of MilliQ filitered distilled H20. 
**Important:  Guanidine is a chaotropic agent and should be handled carefully. 
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